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2. Summary 
 
Prostate cancer is one of the most common cancer types in the Western male 
population. Yet the underlying mechanisms, which lead to the development of 
prostate cancer and especially to androgen-insensitivity, are not fully understood. 
cJun and JunB, two elements of the transcription factor AP-1, have been reported to 
play a role in various cancer types. They have the ability to act both as tumor 
suppressor and as oncogene. Their role in prostate cancer is being discussed 
controversially.  
The aim of this thesis is to analyze the effects of cJun and JunB on the development of 
prostate cancer. Therefore a PB-Cre4 PTEN fl/fl prostate cancer mouse model was 
used, which included knockouts of cJun and/or JunB. These two proteins were 
analyzed selectively by means of histologic assessment, immunohistologic experiments 
and Western blotting. 
cJun showed clear tumor suppressing characteristics. Its knockout increased tumor 
development in prostate cancer mice. Such indicative results could not be attained for 
JunB, its knockout had neither positive, nor negative effects on tumor development in 
the prostate. 
Our identification of cJun as tumor suppressor in mice prostate cancer correlates with 
the literature supporting cJun as a tumor suppressor in human. These data should be 
validated and complemented by data resulting from clinical trials. 
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3. Zusammenfassung 
 
Prostata-Karzinome gehören zu den häufigsten Krebsarten von Männern in der 
westlichen Zivilisation. Trotzdem sind die Mechanismen, welche in der Entstehung von 
Prostata-Krebs und vor allem in der Entwicklung einer Androgen-Insensitivität eine 
wichtige Rolle spielen, bislang noch nicht vollständig bekannt. 
cJun und JunB sind zwei Elemente des Transkriptionsfaktors AP-1, deren Bedeutung 
schon in verschiedensten Krebsarten nachgewiesen wurde. Sie können sowohl als 
Tumor-Suppressor als auch als Onkogen wirken. Ihre Rolle im Prostata Krebs wird bis 
dato kontrovers diskutiert. 
Ziel der vorliegenden Arbeit ist es, die Wirkung der beiden Faktoren cJun und JunB auf 
die Entstehung von Prostata-Karzinomen näher zu untersuchen. Hierfür wurde ein  
PB-Cre4 PTEN fl/fl Mausmodell verwendet. Dieses Mausmodell beinhaltet neben der 
Generierung von Prostatakrebs Mäusen auch einen zusätzlichen Knockout von cJun 
und/oder JunB, um den Einfluss dieser beiden Proteine noch selektiv untersuchen zu 
können. Eine Analyse der Mäuse wurde mit Hilfe einer histologischen Begutachtung, 
immunhistologischen Experimenten und Western-Blotting durchgeführt. 
cJun zeigte in den Experimenten Tumor supprimierende Eigenschaften. Der knockout 
von cJun in den Prostatakrebsmäusen verstärkte das Tumorwachstum. Für JunB 
konnten solche eindeutigen Hinweise nicht gefunden werden. Der knockout von JunB 
wirkte weder positiv noch negativ auf das Tumorwachstum in der Prostata.  
Die starken Hinweise von cJun als Tumorsupressor in Prostata-Krebs Mäusen sind 
bisher noch nicht beschrieben und unterstützen eher das in der Literatur beschriebene 
Bild cJun´s als Tumor-Suppressor. Diese Daten sollten weiter validiert und mit 
humanen Daten komplementiert werden. 
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4. Aim 
 
The estimated prevalence of cancer cases in 2008 seems to be approximately 12.7 
million people worldwide. Prostate cancer (PCa) was, and probably still is, the most 
common cancer among men in the Western civilization [BRAY et al., 2012].  
In 2009,25% of diagnosed malign male tumors in Austria were prostate tumors and 
PCa was the third most common cancer death in Austrian men [STATISTIK AUSTRIA, 
2011]. 
Recently there has been some progress to resolve the molecular pathogenesis of PCa, 
however the exact underlying mechanisms are still to be understood. Some of the 
involved processes are well known while many other factors, which influence the 
development of PCa, are not yet discovered. Therefore, describing and understanding 
these factors, plays a major role in developing new treatment strategies in order to 
treat patients with this condition. The Androgen Receptor (AR) plays a pivotal role in 
PCa. The aim of a number of studies is to investigate its various functions and how the 
mechanisms are controlled.  
The Activator Protein 1 (AP-1) transcription factor complex can influence the AR in 
different ways. cJun and JunB are two important members of AP-1. It has been shown 
that both play a role in the development of tumors. Whether they act as oncogene or 
as tumor suppressor depends on various factors. The role of cJun in PCa is 
controversial. As of now, it is unclear whether cJun and JunB act as oncogene or as 
tumor suppressor in PCa. 
Most experiments dealing with PCa were carried out using cell cultures and some were 
carried out on biopsy specimen of human prostate tissue, like formalin-fixed paraffin 
embedded tissue (FFPE). FFPE is the standard method to fixate and store tissue 
samples. In these samples even protein modifications and phosphorylations may be 
stabilized. With the relatively new reverse phase protein array (RPPA), FFPEs can be 
analyzed with high throughput and minimal sample wastage [BERG et al., 2010]. 
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To investigate prostate cancerogenesis in greater detail, we took advantage of the 
Probasin (Pb) Cre4 PTENloxp/loxp (PTENpc -/-) mouse model [KASPER, 2005]. This 
conditional PTEN knockout model was crossed with various other genetically 
engineered mice (GEM) to investigate the influence of these genes on the 
development of PCa.  
We were interested in the effect of loss of either cJun or JunB or both alleles on 
PTENpc-/- prostate cancerogenesis.  
In this thesis the first aim was to crossbreed the PTENpc-/- prostate cancer mouse model 
with an additional knockout of cJun and/or JunB to analyze the role of both AP-1 
members in PCa. One focus was to investigate the relationship between cJun, JunB and 
the AR.  
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5. Introduction 
 
The prostate is an important part of the male reproductive system. The prostate gland 
is located below the bladder around the urethra. It is composed of fibromuscular 
stroma and epithelial glands. The stroma consists of smooth muscle cells, fibroblasts, 
endothelial and dendritic cells, nerves and some infiltrating cells, e.g. lymphocytes and 
mast cells. The epithelial layer of the glands is built up of basal cells, luminal secretory 
cells, and endocrine cells. The secretory cells have various important functions, one of 
which is the secretion of prostate specific antigen (PSA) and some components of the 
prostatic fluid. They also express the Androgen Receptor (AR). The epithelium of the 
prostate gland appears to be the origin of the prostate adenocarcinoma [FELDMANN 
and FELDMANN, 2001]. 
The stromal-epithelial crosstalk also plays a critical role in the development of PCa. 
Numerous paracrine factors which are characteristic for the complex interactions of 
stromal and/or prostate cancer cells have been described, e.g. TGF-β, PDGF, GSTP1 or 
RARβ2. Angiogenesis, an increase in myofibroblasts and an amplification of the 
extracellular matrix are characteristic signs of a reactive stroma [NIU and XIA, 2009]. 
The diagnosis of PCa used to mainly concern elderly men. However, in the last few 
decades the risk to develop PCa before 75 years of age increased dramatically. In 2009 
the risk to develop PCa before the age of 75 was 9% in Austria [STATISTIK AUSTRIA, 
2011]. This trend and the increasing life expectancy of males are two of the reasons 
why an intensified research in the field of PCa is important. 
 
5.1. Screening Test 
Localized PCa is hard to detect because in the beginning of PCa very few patients have 
characteristic symptoms. For this reason screening tests were developed.  
A Digital Rectal Examination (DRE) executed by a physician was the primary screening 
method for a long time. There are two major disadvantages connected to the DRE. The 
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first issue is that there is a known interobserver bias and secondly, as soon as the 
prostate is palpable in the DRE, the state of the cancer is usually already advanced 
[HOFFMANN, 2011]. 
Today the standard screening method is the measurement of the PSA. This protein is 
an androgen regulated serine protease and is produced by the prostatic epithelial cells 
[FREEDLAND, 2011]. PSA can be measured in the blood serum. The normal range is 
between 0-4 ng/ml and an elevated level of PSA can be associated with PCa. A 
disadvantage of this screening method is that many results are false positive. This can 
be due, for example, to benign prostatic hyperplasia (BPH), cystitis, prostatitis, or 
perianal trauma [HOFFMANN, 2011]. Also a normal level of PSA does not necessarily 
ensure the absence of PCa. 
To confirm the results of DRE and the PSA level a prostate biopsy must be taken. A 
pathologist histologically examines the prostate tissue for tumor occurrences. 
The prostate tissue is graded by the Gleason System according to the 2005 ISUP 
modification. This grading system assesses 5 different “patterns” ranging from 1, 
standing for least aggressive tumor, to 5, for most aggressive tumor (Figure 1). The 
affected prostate often shows different grades of PCa [EPSTEIN et al., 2005].  
To determine the Gleason score the two most frequent tumor patterns (grades) are 
added (for example grade 3+ grade 4 = Gleason Score of 7), which was shown 
statistically to be of high prognostic value and is guidance for clinical and therapeutic 
decision [THOMPSON and THRASHER, 2007]. 
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Figure 1: ISUP Modified Gleason System [EPSTEIN et al., 2005]. 
It is further important to analyze in which degree the tumor has infiltrated the prostate 
and disseminated into other tissues, e.g. lymph nodes and bone tissue. With this 
information the tumor can be classified by a staging system, such as TNM classification 
of the UICC (Greene and Sobin, 2009).The patient risk of disease recurrence or 
progression can be stratified in low and high risk groups. These stratification schemes 
involve the PSA level, the Gleason Score, and the tumor staging and are associated 
with the risk of PSA failure and the various treatment regimens of PCa, e.g. radical 
prostectomy, chemotherapy or external beam radiotherapy [THOMPSON and 
THRASHER, 2007]. The risk stratification can be used to choose the treatment 
according to the risk of relapse [FREEDLAND, 2011]. 
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5.2. Treatment 
The optimal strategy for tumor treatment should not only include risk stratification but 
also life expectancy and the overall health status of the patient [FREEDLAND, 2011]. 
For low risk prostate cancer patients many treatment opportunities are available and 
controversially discussed. Some patients undergo an active surveillance with periodic 
evaluation of the PSA level, DRE, or Gleason score progression on rebiopsy 
[THOMPSON and THRASHER, 2007]. These patients avoid adverse effects by curative 
therapies and their risk to die from PCa is low.  
Many patients decide for an active treatment of their disease. Most common curative 
options are radical prostatectomy (RP), external beam radiotherapy (EBRT) and 
brachytherapy [FREEDLAND, 2011]. Common adverse effects include impotence, and 
incontinence. 
Androgen Deprivation Therapy (ADT) is another treatment option for PCa. If surgical 
treatment is no option ADT is the mainstay for locally advanced and metastatic PCa. It 
is also commonly employed in recurrent PCa after RP [YAMAOKA et al., 2010]. In early 
stage disease ADT is being discussed controversially. 
Androgens play an important role in growth and proliferation of the prostate. The 
testicles produce the majority of the circulating androgens and the minor part is 
produced by the adrenal gland. Testosterone is the main circulating androgen. 
In the blood testosterone is bound to albumin or sex-hormone-binding globulin 
(SHBG). In the prostate cells it is converted into Dihydrotestosterone (DHT), which has 
an up to 10 times higher affinity to the Androgen Receptor (AR) than testosterone. 
Testosterone respectively DHT binds to the AR. The AR is bound to heat shock proteins 
like HSP 90, 70 or 56. If a ligand like testosterone or DHT binds to the AR-HSP complex, 
the AR undergoes conformational change and the HSPs dissociate. The AR translocates 
into the nucleus and dimerizes with another AR molecule. This AR homodimer binds to 
the androgen-responsive element (ARE) of the target gene. The ARE-bound AR 
homodimer recruits coactivators or corepressors (which are co-regulators) or interacts 
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directly with the transcription preinitiation complex of the target gene to either 
activate or repress these target genes (Figure 2) [HEEMERS H. and TINDALL D., 2007]. 
AR regulation results in production of PSA, which stimulates growth and survival of 
cells. 
This pathway plays a main role in the development of PCa. Therefore androgens are a 
main target for treatment of PCa. 
 
Figure 2: AR interaction: Testosterone enters the androgen-responsive cell. It is then reduced to DHT 
and binds to the AR within the cytoplasm. HSP meanwhile dislocates from the AR. The AR then 
dimerizes and binds to the DNA [Feldmann and Feldmann, 2001]. 
ADT causes androgen ablation, which results in a lower level of PSA and decreased 
testosterone level [CANNATA et al., 2012]. 
The first therapeutical approach, ADT, was aiming at the androgen production in the 
testicles. Orchiectomy and later GnRH agonists are also established methods. Even 
when serum testosterone is decreased to castrate level prostatic androgen 
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concentration remains at 10-25 % of the normal androgen level. GnRH agonists 
prevent the release of Luteinizing Hormone (LH) that is responsible for the androgen 
production in the testis. Estrogens are no longer used because of their cardiovascular 
side effects [CANNATA et al., 2012]. The greatest disadvantage of this method is the 
development of resistance to ADT 2-3 years after start of therapy. This is usually 
recognized by a newly found increase in PSA in the face of castrate levels of 
testosterone [FREEDLAND, 2011]. At this point the disease is called castrate resistant 
prostate cancer (CRPC). Symptomatic CRPC is associated with a poor prognosis 
[YAMAOKA et al., 2010]. 
Another important pathway that has a prominent influence on the development of 
PCa is the PI3K/Akt/mTOR signaling pathway. This pathway is up regulated in 30-50% 
of PCa. This up regulation is often associated with the loss of the tumor suppressor 
gene PTEN, which acts as negative regulator of this signaling pathway. Alterations of 
the PI3K/Akt/mTOR signaling pathway show an increase in tumor grade, tumor stage 
and risk for recurrence. Many inhibitors for this pathway have been developed. The 
most promising are mTOR inhibitors [MORGAN et al., 2009]. 
 
5.3. Androgen Receptor and Prostate Cancer 
For obvious reasons there is a need to explain the mechanisms underlying CRPC, as 
well as for solutions to overcome this problem. The exact molecular mechanisms 
responsible for CRPC are not yet fully understood. Many studies support the 
importance of the physical presence and the activity of AR [KOOCHEPOUR, 2010].  
Androgen Receptor is a nuclear transcription factor which belongs to the steroid-
thyroid-retinoid nuclear-receptor superfamily. The biologic activities of androgens are 
mediated via AR. This is essential for the normal growth of the prostate and for the 
pathogenesis of PCa [ROSS, 2007]. 
An altered expression level of AR is one possible mechanism for resistance to ADT.  
AR amplification leads to enhanced ligand–occupied receptor content even in a low 
androgen environment [FELDMANN and FELDMANN, 2001]. 
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An increased AR sensitivity is another way to overcome the castrate level of 
androgens. In CRPC, cells require a four orders of magnitude lower concentration of 
DHT for growth stimulation as compared to androgen dependent LNCaP cells 
[FELDMANN and FELDMANN, 2001].  
Also the increasing rate of converted testosterone to DHT in prostate cells is a 
possibility to get over ADT.  
All the mechanisms mentioned above should be prevented by an AR-blockade. In total 
androgen blockade (TAB), one method to inhibit the AR-activity, antiandrogens 
displace androgens from the AR and block the transcriptional effects of the AR. Drugs 
like flutamide, nilutamide and bicalutamide are currently used antiandrogens.  
However, their affinity to the AR is low and all of these antiandrogens eventually fail 
after a few years of treatment. In these patients the PSA level rises again and the 
clinical symptoms return [SADAR 2012]. 
First generation antiandrogens didn’t seem to provide any survival benefit. An 
explanation for this phenomenon could be intratumoral de novo synthesis of 
androgens. New generations of antiandrogens try to also block these intratumoral 
androgens [YAMAOKA et al., 2010]. 
Another alteration that occurs in PCa is AR mutation. In some cases prostate cells with 
AR mutations can circumvent the growth regulation by androgens. LNCaP cells with a 
mutation at codon 877 can also be stimulated by nonandrogenic steroids like 
estrogens or antiandrogens like flutamide. In this case antiandrogens can act adversely 
as AR activator [KOOCHEPOUR, 2010].  
Therefore a new generation of antiandrogens was developed. These new 
antiandrogens have a higher affinity to the AR and work by different mechanisms than 
the currently approved antiandrogens e.g. EPI-001. Several small inhibitor molecules 
have been discovered, for example Pyrvinium pamoate that alters the confirmation of 
the AR. This small inhibitor protein was tested in a combination with bicalutamide and 
showed a much higher decrease in prostrate weight than bicalutamide alone [SADAR 
2012]. 
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5.4. AP-1 
One co-regulator of the AR is the activating-protein 1 (AP-1). In this thesis the 
relationship between AR and AP1 in prostate cancer shall be investigated.  
AP-1 is a dimeric transcription factor that is composed of members of the protein 
families Jun, Fos, ATF, and MaF. Jun (cJun, JunB, and JunD) and Fos(c-Fos, Fos-B, Fra-1, 
and Fra2) are the major subfamilies. The AP-1 protein complex can either be homo- or 
heterodimeric, quite contrary to Fos proteins that cannot homodimerize. The varied 
combinations of AP-1 proteins determine the regulated genes by affinity and binding 
specifity. The dimerization of AP-1 is promoted by a leucine zipper motif and has a 
basic domain to interact with the DNA. [EFERL and WAGNER, 2003] 
It recognizes the TPA responsive element (TRE) and the cyclic AMP responsive element 
(CRE). Positive or negative regulation of target genes of AP-1 depends on dimerization 
composition, the abundance of dimerization partners, posttranslational modifications 
and also the interaction with other proteins [VESELY et al., 2009]. 
 
5.5. cJun and JunB 
In this thesis the focus lies on cJun and JunB, two members of the Jun subfamily. They 
are well investigated and show high potential in the regulation of tumorigenesis.  
Translational control mechanisms can control the abundance of AP-1 proteins. The 
translation of JunB is regulated by mTOR. The control mechanisms for the mRNA of 
cJun are CAP-dependent or CAP-independent and regulated via IRES, the internal 
ribosome entry segments [VESELY et al., 2009]. 
Posttranslational modifications play an important role in the activity and binding 
specificity of cJun and JunB. The principal activation of cJun and JunB occurs via 
phosphorylation. In general extracellular signals are mediated through protein kinase 
cascades that lead to phosphorylation of the specific transcription factor.  
Detailed information on the regulation of phosphorylation of cJun exists and is 
described below. JunB phosphorylation mechanisms have hardly been investigated 
[PIECHACZYK and FARRAS, 2008]. 
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Figure 3: Feed-forward regulation and expression of cJun. Intracellular cJun-phosphorylation of the 
transactivation region leads to AP-1-activation which in turn leads to increased cJun expression 
[MENG and XIA, 2011]. 
cJun has five serine and threonine residues where phosphorylation can take place. 
Upstream the DNA-binding site three phosphorylation sites exist and two sites are 
located in the N-terminus (Figure 3) [MENG and XIA, 2011]. 
There is a feed forward mechanism between AP-1 and cJun expression. AP-1 
stimulates the cJun promoter and gene expression. Upon expression cJun in turn 
increases AP-1 and thereby potentiates the cJun promoter activation. Through this 
autocrine amplification loop cJun is able to convert transient biochemical signals to 
long running AP-1 activity [MENG and XIA, 2011]. 
Phosphorylation of cJun takes place via the mitogen activated protein kinase (MAPK) 
cascade. MAP-3K is induced by physiological and environmental factors like mitogens 
and stress (TNF, UV light). It catalyzes MAP-2K (MEK 1-4, 6 and 7) by phosphorylation. 
MAP-2K in turn activates MAPK. Three groups of MAPK exist: JNK, ERK, and p38. For 
the regulation of cJun phosphorylation of JNK and ERK is essential (Figure 4) [MENG 
and XIA, 2011]. 
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Figure 4: Signaling pathways leading to cJun phosphorylation [MENG and XIA, 2011] 
GSK-3 and CKII can phosphorylate cJun at the c-terminal domain. Thereafter, cJun is in 
a non-binding state. ERK can activate the S6 kinase that in turn inactivates GSK-3. An 
increased level of ERK leads to dephosphorylation of cJun in the C-termini and 
therefore enhances the binding activity to the DNA. JNK can bind to the transactivation 
domain of cJun and phosphorylates cJun at the N-termini [MENG and XIA, 2011]. 
DNA binding and transcription of cJun can be enhanced by the tumor promoter 
phorbol-ester (TPA). It decreases the phosphorylation in the C-termini and thereby 
increases the DNA-binding of cJun. Furthermore, TPA induces the transactivation 
activity of cJun by increasing the N-terminal phosphorylation [MENG and XIA, 2011]. 
As mentioned before there is no detailed information on JunB phosphorylation, but it 
is known that the phosphorylation sites at serine 63 and 73 for JNK are not conserved 
in JunB [PIECHACZYK and FARRAS, 2008]. On the other hand Li et al discovered a 
phosphorylation of JunB by JNK at threonine 102 and 104. Thus phosphorylated JunB 
stimulates IL-4 expression in T-helper cells [LI et al 1999]. 
The influence of cJun and JunB on the cell cycle partly explains their role in 
tumorigenesis. They regulate various genes that significantly affect the cell cycle and 
apoptosis (Table 1). 
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Gene product Activity cJun JunB 
Cyclin D1 Proliferation ↑ Up Down 
p53 Proliferation ↓ 
Apoptosis ↑ 
Down - 
p21Cip1 Proliferation ↓ Down - 
p16INK4 Proliferation ↓ 
Apoptosis ↑ 
Down Up 
p19ARF Proliferation ↓ 
Apoptosis ↑ 
- - 
GM-CSF Proliferation ↑ Up Down 
KGF Proliferation ↑ Up Down 
HB-EGF Proliferation ↑ Up - 
FL1 Proliferation ↑ Up Up 
FasL Apoptosis ↑ Up - 
Fas Apoptosis ↑ Down - 
Bcl3 Apoptosis ↓ Up - 
Table 1: AP-1-regulated genes, that significantly affect cell cycle progression and apoptosis [SHAULIAN 
and KARIN, 2002]. 
In quiescent cells expression of cJun and JunB is low. They reach their expression peak 
during G0/G1 transition and return to an intermediate level. For cell cycle progression 
towards S phase this induction is instrumental. The high expression of cJun in G1 
results from N-terminal phosphorylation. During the rest of the cell cycle cJun levels 
remain constant. JunB levels increase in G1 phase and on entering S phase. In G2/M 
phase the level of JunB is low (Figure 5) [PIECHACZYK and FARRAS, 2008]. 
 
Figure 5: cJun and JunB levels during the cell cycle. Both, cJun and JunB levels, peak just after the cell 
leaving G0 phase, cJun then retains quite constant concentration whereas JunB levels drop 
dramatically when entering the M phase, then returns to normal levels again in G1 phase 
[PIECHACZYK and FARRAS, 2008]. 
cJun induces the transcription of cyclin D1. Furthermore, cJun directly represses p53 
gene transcription. cJun also has the ability to decrease the transcriptional activity of 
the tumor suppressor p53. It reduces the ability of p53 to activate the p21 gene. P21 
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inhibits the cyclin dependent kinase (CDK) [SHAULIAN and KARIN, 2002]. Taken 
together cJun positively regulates the cell cycle through the induction of cyclin D1 
transcription and the repression of p21 transcription (Figure 6). 
All these effects of cJun boost proliferation and in case of proliferation are associated 
with cancerogenesis. In diseases like Anaplastic Large Cell Lymphoma (ALCL) and 
Hodgkin´s disease cJun is overexpressed. It suppresses the apoptosis in ALCL cells and 
increases proliferation in Hodgkin’s disease [SHAULIAN, 2010]. 
On the other hand cJun can also act proapoptotic and antiproliferative. It induces 
apoptosis following adequate DNA damage after exposing cells to UV light. cJun is also 
involved in DNA repair mechanisms. cJun-deficient MEF`s (mouse embryonic 
fibroblasts) show an impaired repair mechanism and strongly damaged DNA. It 
depends on the extent of damage by UV-radiation whether cJun promotes DNA-repair 
and cell cycle reentry or apoptosis. [SHAULIAN, 2010]. 
cJun can also regulate proapoptotic genes like Fas, FasL, Bim and antiapoptotic genes 
like Bcl3. The balance of expression of such genes regulates whether the cells survive or 
undergo apoptosis (Figure 6) [SHAULIAN and KARIN, 2002]. 
 
Figure 6: Effects of cJun in apoptosis. a) Upon UV-exposure of cells showed that cJun mediates 
induction of pro-apoptotic genes (FasL, Bim) as well as up-regulation of anti-apoptotic genes (Bcl3) 
and downregulation of pro-apoptotic gene products (Fas). The sum of these regulations leads to the 
cell undergoing apoptosis or survival respectively. b) cJun leads to downregulation of p21, which is, on 
the whole, an anti-apoptotic action. Yet cells exposed to UV will still undergo apoptosis, if cell damage 
is sufficient [SHAULIAN and KARIN, 2002]. 
Both cJun and JunB expression elevates the level of Dmp1. This tumor suppressor 
enhances the expression of p19ARF, another tumor suppressor that increases p53 
activity. This is due to interaction with Mdm2 [SHAULIAN and KARIN, 2002]. 
In summary the function of cJun is controversial and depends on many factors. 
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Like cJun, JunB can also act as a tumor suppressor and, in a different setting, as 
oncogene. 
In ALCL JunB expression is increased and enhances proliferation. This is due to the 
fusion protein npm-alk (anaplastic lymphoma kinase). This oncogenic protein increases 
JunB levels via the mTOR pathway [SHAULIAN, 2010]. 
The function of JunB in the cell cycle is the repression of the promoter of cyclin D1 and 
the induction of p16. Overexpression of JunB leads to an upregulation of p16 and 
thereby inhibits phosphorylation of Rb by CDKs. This prevents the transition from G1 to 
S-phase. Overexpression of JunB also inhibits the induction of cyclin D1 by cJun. JunB 
acts antiproliferative and antagonizes cJun, but it also has promoting activities in the 
cell cycle. JunB is needed for a rapid progression during S-phase. It positively regulates 
the transcription of cyclin A2 [SHAULIAN and KARIN, 2002]. 
Before mitosis JunB degrades depending on phosphorylation. The decreased JunB 
levels during mitosis ensure an adequate progression into the next G1-phase (Figure 7) 
[PIECHACZYK and FARRAS, 2008]. 
To sum up the effects of JunB it can inhibit the cell cycle by antagonizing cJun, 
repressing cyclin D1 and inducing p16. On the other hand JunB is important for cellular 
proliferation in ALCL and can promote the cell cycle through induction of cyclin A2. 
 
Figure 7: Cell cycle-inhibiting and -promoting activities of JunB. JunB mediates up-regulation of p16 
and inhibits cJun, thereby inhibiting the cell cycle. It also induces Cyclin A2, thereby driving the cell 
cycle. The overall effect depends on the sum of interactions [PIECHACZYK and FARRAS, 2008]. 
The effects of cJun and JunB greatly depend on the circumstances. The question 
remains, how their expression impacts PCa and its development. 
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5.6. cJun and JunB and AR 
The expression levels of cJun in the prostate and therefore its relevance to prostate 
tissue is being discussed controversially. In a study of Ricote et al p-cJun levels in 
normal prostate, benign prostate hyperplasia (BPH) and PCa were observed via 
immunohistochemistry and Western Blotting (WB). In both experiments the normal 
prostate tissue and PCa samples showed no expression of p-cJun. Interestingly in 27% 
of BPH samples p-cJun expression was observed [RICOTE et al., 2003]. 
On the other hand a study of Tiniakos et al showed cJun expression in 13 of 16 
(81.25%) patients with BPH. In PCa 31 of 36 (86.1%) patients showed cJun expression. 
Additionally, they found no correlation between the expression of cJun and PSA-level 
or Gleason score [TINIAKOS, 2006]. 
Many studies tried to investigate the various mechanisms in which cJun is involved in 
PCa or influences the AR. It has been shown that cJun functions as coactivator of AR 
that stimulates the transactivation of AR. This occurs via mediation of receptor 
dimerization and a subsequent binding to DNA [CHEN et al., 2006]. 
Furthermore in LNCaP cells a direct correlation between endogenous level of cJun and 
the activity of AR transcription and also with the androgen regulated genes was 
observed. The function of cJun as AR-coactivator in LNCaP cells seems to be more 
sufficient for the regulation of androgen dependent growth than AP-1 transactivation. 
This was tested in a cJun mutant LNCaP cell line that is less active in AP-1 
transactivation and fully active in AR-coactivation. The results show an increase of 
proliferation in androgen dependent LNCaP cells [CHEN et al., 2006]. 
cJun is also involved in protein-protein interactions that can influence the AR function. 
If cJun, Sp1, and AR form a protein complex induced by the plant-polyphenol Quercitin, 
the function of AR appears to be suppressed in PCa cells. This complex inhibits the 
positive effect of Sp1 on AR transcriptional activity by the transcriptional function of 
AR to regulate androgen dependent genes [YUAN et al., 2010]. 
On the whole, it has been shown that the impact of cJun in PCa is multifactorial and 
that it is being discussed controversially. 
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Studies concerning the influence of JunB on PCa are rare. Some few studies have 
analyzed the JunB expression profile in PCa but none have investigated the 
relationship of JunB and the AR. 
An extensive study of expression profiles in PCa also examined JunB expression. They 
investigated donor-, primary and metastatic PCa. High expression of JunB was 
observed in primary prostate samples. In donor and metastatic tumors a low JunB 
expression was detected (Figure 8) [CHANDRAN et al., 2007].  
 
Figure 8: JunB expression of donor prostate samples, primary and metastatic PCa. In primary PCa JunB 
seems to be up-regulated [CHANDRAN et al., 2007]. 
In another study an inverse correlation between JunB expression and an increase of 
the pathological grade in primary and metastatic human PCa was detected. JunB 
expression was examined immunohistologically. In normal prostate epithelium the 
expression of JunB is 61.7± 3.45%. The higher the Gleason grade, the lower was the 
JunB expression (GS<6 43.3± 4.44% and GS=8 11.6 ±1.94%). In metastasis just 1.93± 
0.26% JunB expression was observed (Figure 9) [KONISHI et al., 2008]. Based on this 
study JunB could have tumor suppressor activities. 
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Figure 9: JunB expression in primary and metastatic PCa. With increasing Gleason Score JunB levels 
decrease significantly [KONISHI et al., 2008]. 
Further research work directly concerning cJun, JunB and AR was done by Puhr et al. 
unpublished. Six prostate cell lines were analyzed for their expression of AR, cJun, and 
JunB using Western Blotting. Two wildtype prostate cell lines (RWPF-1 and BPH-1), two 
androgen dependent (VCaP and LNCaP), and two androgen independent (DU145 and 
PC3) prostate cancer cell lines were investigated (Figure 10). 
In the wildtype and the androgen independent prostate cell lines the AR was rarely 
expressed. However, in the androgen dependent prostate cell lines the AR was highly 
expressed. cJun and JunB act exactly in the opposite way. In RWPF-1, BPH-1, and in 
DU145, PC3 cJun and JunB were highly expressed. In contrast the VCaP and LNCaP cells 
did not express both AP-1 proteins. In prostate cell lines AR, cJun, and JunB seem to 
directly influence each other [PUHR et al., unpublished). 
Taking together, the results are controversial. AP-1 components may have many 
different effects in PCa. Some mechanisms are fully understood but many still remain 
unclear.  
The influence of cJun and JunB in prostate cancer mouse models is barely studied. 
They are, however, very promising targets in PCa development, even though the 
existing data are rather controversial, possibly due to the complexity of the involved 
mechanisms. Since it is known, that the AR plays an important role in PCa genesis the 
21 
 
 
aim of thesis at hand will be to take the current research to the next level and study 
the effects of a cJun and/or JunB knockout on the AR in mice. 
 
Figure 10: Protein expression of AR, cJun and JunB in wt, androgen dependent and androgen 
independent prostate cancer cell lines. No elevated AR expression is seen in the wt prostate cells 
(RWPE-1, BPH-1), yet cJun and JunB expression is up-regulated. In the androgen dependent prostate  
cancer cell lines (LNCaP, VCaP) the AR expression is increased, whereas cJun and JunB expression is 
decreased. In the androgen-independent prostate cancer cell lines (PC3, DU-145) the AR expression is 
decreased and cJun and JunB expression is increased again [PUHR et al., unpublished data]. 
In mouse and human prostates many anatomical similarities exist that make it possible 
to take GEM for investigating human diseases like PCa.  
Both species have a male accessory organ that develops from the urogenital sinuses 
and the Wolffian ducts. Their prostates form lobular glands and are androgen specific. 
Both have differentiated prostate epithelial cells and their function is similar 
[SHAPPELL et al., 2004].  
Obviously, there are also anatomical differences between mouse and human prostates 
which have influence on the pathological interpretation of the mouse model. 
In the adult human organism the prostate is no longer clearly separated into lobular 
structures, as it is in mice. It is rather divided into different zones: periurethral 
transition zone (TZ), peripheral zone (PZ), and central zone (CZ). BPH is often formed in 
the TZ and PZ is often the origin of PCa. CZ is seldom the origin of PCa (Figure 11) 
[SHAPPELL et al., 2004]. 
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Figure 11: a) Schematic anatomy of zones of the prostate gland. CZ = central zone; TZ = periurethral 
transition zone; PZ = peripheral zone [CURRAN et al., 2007]. b) HE prostate gland 
[http://www.med.umich.edu/histology/endoRepro/questions/slide281orientation.jpg]. 
As mentioned before the mouse prostate is composed of distinct lobes: Apical Prostate 
(AP), Ventral Prostate (VP), and Dorsal and Lateral Prostate (DLP)). The lobes are 
surrounded by a capsule lined with mesothel (Figure 12) [SHAPPELL et al., 2004].  
For investigation of PCa all different mouse prostate lobes are equally relevant. In each 
mouse prostate gland cell populations are normal and homologous to the human 
prostate. There is a basal cell layer, luminal secretory cells and some neuroendocrine 
cells [SHAPPELL et al., 2004]. 
 
Figure 12: a) Schematic diagram of the mouse genitourinary bloc. UB = urinary bladder; VP = ventral 
prostate; LP = lateral prostate; DP = dorsal prostate; SV = seminal vesicals; CG = coagulating gland or 
anterior prostate; DD = ductus deferens; UR = urethra. b) Microscopic section of the mouse prostate 
gland. 1 = urethra; 2 = ductus deferens; 3 = ampullary glands; 4 = venral prostate; 5 = lateral prostate; 
6 = dorsal prostate [SHAPPELL et al., 2004]. 
PCa does not develop spontaneously in mice [SHAPPELL et al., 2004]. For research in 
the field of PCa in mice some genetically engineered mice (GEM) were created.  
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Traditional gene targeting has some limitations and did not result in good PCa models. 
In conventional knockout mice the timing of gene disruption is not under the 
researcher’s control. However, this is pivotal in a PTEN PCa model because the 
knockout of PTEN during embryogenesis is lethal. Aside from the timing it is better that 
the gene disruption occurs only in specific celltypes or tissues. Both these 
requirements are met using a conditional knockout strategy [STRICKLETT et al., 1999].  
The Probasin Cre4 PTENloxp/lox system is a frequently used model to simulate PCa in 
mice. With this PTEN model the development, the tumor progression and metastasis 
of PCa can be observed [KASPER, 2005]. 
The Cre loxP recombination system is conditional, cell type-, and tissue-specific. The 
limitation of this method is the availability of a specific promoter. Cre is a site specific 
DNA recombinase. Between loxP sites Cre excises DNA sequences [WU et al., 2001]. To 
drive Cre expression in the prostate the Probasin promoter seems to be a good choice. 
Probasin expression is regulated by androgens and primarily observed in differentiated 
secretory epithelial cells [JOHNSON et al., 2000]. 
Expressed with the Probasin promoter Cre activity was observed in luminal epithelium 
of the prostate lobes but not in basal cells. In prostatic buds of newborns the Cre 
activity was low but an increasing Cre expression was detected until adulthood [WU et 
al., 2001].  
The deletion of PTEN in the prostate is very critical for tumor development. PTEN is a 
tumor suppressor located on chromosome 10. The loss of PTEN is frequently mapped 
in primary human PCa. It is a lipid phosphatase and dephosphorylates products  
(3-phosphoinosites) of the PI3K-pathway. 3-phosphoinosites can activate survival 
kinases such as Akt. The Akt pathway controls cell cycle progression, cell proliferation 
and the escape from apoptosis via MDM2, p21, p27, Caspase9, GSK3 and others. PTEN 
negatively regulates the Akt-pathway [HOLLANDER et al., 2011].  
Taken together, to create a PCa mouse model such as PB Cre4 PTENloxP/loxP loxP sites to 
the flanking regions of the PTEN gene have to be inserted. In another mouse the 
transgene Cre had to be inserted into the Probasin promoter region. Breeding the 
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PTENloxP/loxP mouse with the PB Cre mouse leads to excision of PTEN in prostate 
epithelial cells (PTENpc-/-). In all other cell types and tissues of the mouse PTEN remains 
still active (Figure 13).  
 
Figure 13: Cre/lox System. Cre+ mouse crossed with a mouse with a target gene with loxP sites leads 
to excision of target gene in the offspring [PECHIKSER, 2004]. 
If one allele of PTEN is knocked out (PTENpc+/-) the mice develop tumors in the prostate 
from nine month of age. A complete deletion of PTEN leads to PIN lesions at the age of 
six weeks. An invasive and metastatic PCa was observed within a few weeks. Mice of 
this PTEN model are responsive to androgen ablation that prolonged survival. In mice 
with this ADT highly proliferating tumors were found in necropsy. It seems that in this 
model CRPC (castrate resistant prostate cancer) can arise in the mice after ADT 
[HOLLANDER et al., 2011]. 
For the reasoning above the described mouse model was used to conduct the research 
on the thesis at hand. 
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6. Methods 
 
6.1. Mouse Breeding 
Male mice with the genotype Cre+ PTEN fl/fl were used for the experiments. To 
achieve this genotype male Cre+ mice were crossed with female PTEN fl/fl mice in a 
first breeding (figure14). In a second breeding step Cre+ PTEN fl/+ male mice were 
crossed with female Cre- PTEN fl/+ mice to come by the desired genotype, male Cre+ 
PTEN fl/fl. 
 
Figure 14: Breeding scheme of the first breeding. 
The resulting genotypes were used to validate the outcome. With HE-stainings mice 
prostates (wildtype, Cre+ PTEN fl/+ and Cre+ PTEN fl/fl, or wildtype, PTENpc+/-, 
PTENpcfl/fl respectively) were analyzed to occurrence and severity of prostate cancer, 
respectively. These three genotypes were also used to interpret the influence of cJun 
and JunB in the PTEN knock out mouse model. 
In the second breeding step AP1-proteins (floxed alleles of JunB and cJun) were bred 
in. Female Cre+ PTEN fl/fl mice were crossed with male cJun fl/fl and JunB fl/fl mice. 
From the first generation (F1) male Cre+ PTEN fl/+ cJun fl/+ JunB fl/+ and female Cre- 
PTEN fl/+ cJun fl/+ JunB fl/+ were crossed with each other to generate the final 
genotypes (F2: Cre+ PTEN fl/fl with cJun fl/fl JunB fl/fl and Cre+ PTEN fl/fl cJun fl/fl  
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JunB +/+ and Cre+ PTEN fl/fl cJun +/+ JunB fl/fl, or PTENpc-/- cJunpc-/- JunBpc-/-, PTENpc-/- 
cJunpc-/- JunBpc+/+ and PTENpc-/- cJunpc+/+ JunBpc-/- respectively) (Figure 15). 
To better understand the role of cJun and JunB, heterogeneous knock outs of JunB and 
cJun were also analyzed (F2: Cre+ PTEN fl/fl cJun fl/+ JunB fl/+ and Cre+ PTEN fl/fl  
cJun fl/+ JunB +/+, Cre+ PTEN fl/fl cJun +/+ JunB fl/+, or PTENpc-/- cJunpc+/- JunBpc+/- and 
PTENpc-/- cJunpc+/- JunBpc+/+, PTENpc-/- cJunpc+/+ JunBpc+/- respectively) (Figure 15). 
The final outcome of the breedings was comprised of 6 genotypes that were analyzed 
by immunohistochemistry and western blotting. All mouse experiments were carried 
out in accordance to the Austrian Act on Animal Experimentation (GZ 66.009/139-
II/106/2009). 
 
Figure 15: Breeding scheme of the second breeding. 
6.1.1. DNA Isolation 
At the time of determination of the genotype the mice were between three and four 
weeks old. 0.5 cm of the mouse tail was cut off and 400 μl DNA extraction buffer and 
20 μl of proteinase K (10 mg/ml) was added. The tail was incubated over night at 55 °C 
while shaking. The lysed tissue was mixed for 5 min using an Eppendorf mixer. For the 
precipitation of DNA 200 μl NaCl (5M) was added and mixed for an extra 5 min on an 
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Eppendorf mixer. After centrifugation for 10 min at 13000 rpm (15682 x g) (Eppendorf 
5415D) 530 μl were taken from the upper phase and transferred into a new 1.5 ml 
tube. 400 µl isopropanol was added, mixed for 2 min and centrifuged at 13000 rpm for 
5 min. The pellet was washed with 1 ml ethanol (70 %) and centrifuged again a 
13000 rpm (15682 x g) for 5 min. The supernatant was discarded and the pellet 
resuspended in 200 µl aqua dest. The DNA solution was incubated at 37 °C for 2 h 
while shaking. After this procedure the DNA solution was used for PCR or, 
alternatively, stored at 4 °C. 
6.1.2. DNA Amplification with PCR 
DNA Extraction buffer: 
50 mM Tris pH 8 
100 mM EDTA pH8 
100 mM NaCl 
1 %  SDS 
filled up to 50 ml with aqua dest. 
The concentration of the resulting mouse DNA was not high enough for further 
analysis. Using Polymerase chain reaction (PCR) it is possible to create and amplify the 
DNA sequence of interest using specific oligonucleotid primer pairs. 
Used Primers: 
 Sense antisense 
PTEN wt, 
fl 
5’-CTCCTCTACTCCATTCTTCCC-3’ 5’-ACTCCCACCAATGAACAAAC-3’ 
PTEN ∆ 5’-GTCACCAGGATGCTTCTGAC-3’ 5’-ACTATTGAACAGAATCAACCC-3’ 
JunB wt, fl 5’-GGGAACTGAGGGAAGCCACGCCGAGAAAGC-3’ 5’-AGAGTCGTCGTGATAGAAAGGC-3’ 
JunB ∆ 5’-GGGAACTGAGGGAAGCCACGCCGAGAAAGC-3’ 5’-AAACATACAAAATACGCTGG-3’ 
cJun wt, fl 5’-CTCATACCAGTTCGCACAGGCGGC-3’ 5’-CCGCTAGCACTCACGTTGGTAGGC-3’ 
cJun ∆ 5’-CTCATACCAGTTCGCACAGGCGGC-3’ 5’-CAGGGCGTTGTGTCACTGAGCT-3’ 
Cre 5’-CGGTCGATGCAACGAGTGATGAGG-3’ 5’-CCAGAGACGGAAATCCATCGCTCG-3’ 
Table 2: Used sense and antisense primer for PCR for each analyzed gene. 
PCR consists of multiple cycles of varying temperature steps. The cycles are repeated 
several times (see PCR Program below). The first step is the denaturation. Hydrogen 
bonds between complementary bands are disrupted at 90-94 °C resulting in single 
stranded DNA-Templates. The next step is Annealing, in which the primers hybridize 
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with the complementary DNA strands at ≥ 50 °C. The Taq-polymerase synthesizes the 
sequence of interest at 72 °C which is the last step called Elongation. After each cycle 
the DNA amount is doubled. This leads to exponential amplification of the DNA 
template. For the different DNA templates the PCR program has to be adjusted 
frequently resulting in varying PCR programs. 
PCR Program   PCR Program 
Set up PCR reaction reagents Cre, JunB, cJun, cJun∆ JunB ∆, PTEN, PTEN ∆  
12 µl GoTAQ Green MM  5 min at 95 °C   5min at 95 °C   
0.5 µl DMSO    30 sec at 95 °C  30sec at 95 °C  
0.5 µl primer forward  30 sec at 58°C       32x  30sec at 55 °C       32x 
0.5 µl primer reverse  1 min at 72 °C   1min at 72 °C  
0.5 µl aqua dest.   10 min at 72 °C  10min at 72 °C 
6.1.3. Gel electrophoresis 
For analyzing the DNA, the samples were examined using gel electrophoresis. With this 
method DNA fragments are separated by their size. The DNA samples were applied on 
a 2 % agarose gel supplemented with Midori Green (1 µl/100 ml gel). Midori Green 
intercalates with the DNA and absorbs UV light. After gel electrophoresis with 120 V 
for about 15 min the DNA bands were visible under UV light and were analyzed. 
Some primer pairs have two DNA products. The first one is the wt DNA product of the 
target gene and the second is the floxed DNA fragment of the target gene. This is the 
case for JunB, cJun and PTEN. If there are two bands the mouse has one wt allele and 
one floxed allele. If there is just one band the mouse has either wt or floxed alleles, 
which can be differentiated by their molecular weight. 
2 % Agarose gel:    TAE buffer: 
2 g Agarose     96.8 g TRIS 
100 ml TAE buffer    22.8 ml glacial acetic acid 
      40 ml 500 mM EDTA  
      filled up to 20 l with aqua dest. 
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PTEN wt 209 JunB ∆ 320 
PTEN fl 335 cJun wt 280 
PTEN ∆ 849 cJun fl 320 
JunB wt 300 cJun ∆ 600 
JunB fl 350 Cre 455 
Table 3: PCR products in bp. 
 
6.2. Prostate Sample Preparation 
After 19 weeks male mice were sacrificed. The genito-urinary tract with the prostate, 
seminal vesicals, and the bladder was resected and weighed. Thereafter a macroscopic 
picture was taken. The next step was the isolation of the prostate. Care was taken to 
remove as much fat tissue as possible from around the prostate and to avoid inclusion 
of pieces of the bladder or the seminal vesicles into the prostate sample. The whole 
prostate was weighed and then cut up into two pieces. 
One piece was fixed with 4.5 % paraformaldehyde. After dehydration the sample was 
embedded in paraffin and stored at room temperature. The other piece of the 
prostate was first put into liquid nitrogen and later stored at -80 °C. 
The documented body- and prostate weight of the mice was analyzed statistically. First 
the means ( x ) of the body- and prostate weight in each genotype were determined 
and thereafter the standard deviation (s). To relativize the standard deviation and to 
check whether the means were representative for all data the coefficient of variation 
(Cv) was calculated. 
x =
𝑥𝑥1+𝑥𝑥2+⋯+𝑥𝑥𝑥𝑥
𝑥𝑥
  
Furthermore, the results of the genotypes in the bodyweight- and prostate weight 
groups were analyzed by an unpaired T-Test. This Test compares whether the 
differences of two independent groups of samples are statistically significant. This is 
expressed by the p-value. 
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deparaffinization 
6.3. Hematoxylin-Eosin (HE) Staining 
For histochemical staining (HE-staining and IHC immunohistochemistry) 3 µm sections 
were cut off the paraffin block with the prostate sample. The prostate sections were 
placed on microscope slides. 
To evaluate the prostate tissues with different genotypes HE staining was done. This is 
a standard procedure to initially screen whether the tissue samples are regularly 
aligned or irregular as seen, for example, in cancer. After the staining procedure the 
cell nucleus will be colored blue (hemalaun) and the cell plasma will be colored red 
(Eosin). 
The tissue slides were placed in a staining machine (Tissue Stainer COT20, Medite 
GmbH Germany). The progression in the staining program was as follows and done 
automatically. In a first step the tissue samples were deparaffinized. The next step was 
the incubation in hemalaun. A washing step with aqua dest. followed. The third step 
was the incubation in Scott´s Solution (Sott). This is a reagent that blues hematoxylin 
gently. The tissue was washed again with aqua dest. Afterwards the staining with Eosin 
was accomplished and then washed again with aqua dest. In a last step the samples 
were dehydrogenized. The time of incubation was two minutes in each chemical 
solution. 
After the staining procedure the tissue stainings were covered with Eukitt in another 
machine (CV5030, Leica Microsystems, Switzerland). Eukitt is a mounting medium that 
prevents moisture from developing under the cover glass.  
The tissue samples were ready to evaluate under the light microscope. 
Staining cycle:     Products: 
 
Xylol(4x)     hemalaun: 290 ml Papanicolaous  
ethanol 100 %       290 ml aqua dest. 
ethanol 96 % 
ethanol 80 %     Eosin:  150 ml 5 % eosin 
aqua dest.       1 ml 100 % acetic acid 
hemalaun (2x)      up to 580 ml with aqua dest. 
aqua dest. 
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dehydration 
Sott (2x)     Dyes: 
aqua dest. 
eosin (2x)     Papanicolaous 1A  1092532500 Merck  
aqua dest        Millipore, Germany 
ethanol 96 % (2x)    Eosin 5 %  Sigma-ALD, Germany 
ethanol 100 % (2x)    Sott   11241, Morphisto,  
EBE (=n-butyl acetate)       Germany 
 
6.4. Immunohistochemistry 
Using the immunohistochemistry (IHC) the prostate samples of the 5 different 
genotypes (wildtype, PTENpc+/-, PTENpc-/-, PTENpc+/- cJunpc-/- JunBpc+/-and PTENpc+/- 
cJunpc+/- JunBpc-/-) were analyzed regarding 4 different targets (Androgen Receptor, 
cJun, JunB and ki67). All tissue slides undergoing analysis for the same target were 
equally treated at the same time to achieve a comparable result. For wt, PTENpc+/-, and 
PTENpc-/- 5 tissue samples were available, for PTENpc+/- cJunpc-/- JunBpc+/- 4 tissue 
samples were available and for PTENpc+/- cJunpc+/- JunBpc-/- only 1 tissue sample was 
available for comparison during the time of the thesis was performed.  
6.4.1. Deparaffinization and Rehydration 
For immunohistochemical staining the slides were incubated at 56 °C for 1 h. They 
were then place in 100 % Xylol twice for approximately 15 min to deparaffinize the 
sections. To rehydrate the samples, they were incubated in an ethanol series  
(2x 100 %, 1x 96 %, 1x 70 %, 1x 50 %) and twice in aqua dest. for two minutes. 
6.4.2. Pretreatment 
This step is important to disconnect the protein cross-linkings which occurred during 
the formalin fixation. After this process antibodies will be able to bind to epitopes of 
the sample proteins.  
The slides were placed into cuvettes with a special buffer and heated. Which buffers 
and heating methods are used in the pretreatment depends on the particular 
antibody. The antibodies used, their concentration and their particular pretreatment 
are shown in the table below. After heating, the slides were cooled down at room 
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temperature. They were then washed three times with phosphate buffered saline 
(PBS). 
antibody concentration buffer heating Methode 
cJun CS 9165 1:100 (S2369)Citrate pH6, 
Dako, Denmark 
Autoclave  
JunB SC-46 1:300 (S2367) Tris EDTA 
pH9)Dako, Denmark 
Steamer 
AR SC-816 1:300 (S2367) Tris EDTA 
pH9)Dako, Denmark 
Steamer  
Ki67 novocastra 
6002374 
1:1000 (S2369) Citrate pH6, 
Dako, Denmark 
Autoclave  
Table 4: Used antibodies and their conditions for IHC. CS: Cell Signaling Technology (Massachusetts, 
USA); Novocastra: Leica Microsystems (Switzerland); SC: Santa Cruz Biotechnology (California, USA). 
To reduce nonspecific background in the tissue sections some special treatment was 
needed. The slides were incubated in 3 % hydrogen peroxide for 10 min, thereby 
quenching the endogenous peroxidase. Afterwards the slides were washed again 3x 
with PBS. 
6.4.3. Blocking and Antibody reaction 
An Avidin-Biotin Blocking Kit (SP-2001, Vector Laboratories Inc, California, USA) was 
used to reduce the binding of avidin or other components of the Avidin-Biotin System. 
These binding processes can be due to endogenous biotin or biotin binding proteins. 
AvidinD solution was added dropwise on the slides and incubated for 10 min. After 
incubation the slides were washed 3x with PBS-Tween. Then the biotin solution was 
added dropwise on the slides and incubated for 10 min  
A last blocking step and the following steps were accomplished with the IDetect 
Universal Mouse Kit (HRP) (IDSTM003, ID-Labs Inc, Ontario, Canada). A super block for 
7 minutes and a universal mouse block for 1 h were done. After both blocking sessions 
the slides were washed 3x with PBS-Tween. 
Thereafter the primary antibody was added similarly on the slides and incubated over 
night at 4 °C. The primary antibodies were diluted in PBS + 1 % BSA to reach the 
specific concentration (see table 2). 
The slides were washed with PBS-Tween. Then the secondary biotinylated  
(anti polyvalent) antibody was added dropwise on the slides and incubated for 10 min 
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at room temperature. The slides were washed again with PBS-Tween.  
Horse radish peroxidase (HRP) was added on the slides, incubated for another 10 min 
at room temperature and washed 3x with PBS-Tween. 
6.4.4. Emerging 
For emerging of the first slide a sample with an expected positive signal was taken. 
150 µl of the Chromogen/H₂O₂ solution (AEC Chromogen Kit, 17515 ID Labs Inc., 
Ontario, Canada) was added. H₂O₂ acts as a substrate of HRP. This enzyme catalyzes 
the reaction of the colorless 3-Amino-9-Ethylcarbazole (AEC) to its red end product. 
 
Figure 16: Scheme of the functionality of the IHC reaction. After pretreatment and blocking reactions, 
the antigen is treated with the primary and secondary antibody. The second antibody is biotynilated 
and marked with HRP. This enzyme in turn catalyzes the reaction of colorless AEC chromogen to the 
red end product. The amount of conversion corresponding to the intensity of the red product can be 
evaluated under the microscope or with special software like HistoquestTM [modified from 
http://www.piercenet.com/browse.cfm?fldID=5E9905AB-CA02-E370-95DE-C9816CF9F7DC]. 
The time until a strong positive red signal was perceived under the light microscope 
was clocked and was then used as standard timeframe for all other slides treated with 
this antibody. After incubation with Chromogen solution the slides were placed in aqua 
dest. to stop the reaction. 
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6.4.5. Counterstaining 
After the immunohistochemical staining of the target antigen the slides were stained a 
second time with Meyer’s hemalaun (1:5 diluted with aqua dest., 1.09249.0500, 
Merck, Germany) to get a better contrast. 
The slides were incubated with the Hemalaun solution for some seconds and then 
washed with water immediately. The result was monitored under the light microscope. 
This process was repeated until an optimal contrast was achieved.  
After finishing the staining of the slides they were covered with Aquatex (108562, 
Merck, Germany) and a cover slip. The samples were then ready for analyzing and 
were stored at room temperature. 
10x PBS pH 7,5  PBS-Tween 
28.8 g Na2HPO4  2H20  100 ml 10x PBS 
5.2 g NaH2PO4  H2O  0.25 % Tween20  
90 g NaCl    
filled up with a. d. to 1 l filled up with a. d. to 1 l 
6.4.6. Histoquest 
HistoquestTM (TissuegnosticsTM) is a software program for quantification of proteins 
from IHC stained slides. Thus it is easily possible to quantify protein expression levels 
and compare the different groups (genotypes) regarding these observations. 
cJun, JunB, ki67 and androgen receptor expressing cells were defined for each staining 
regimen. Cells can be analyzed with different parameters such as color intensity or 
diameter. For these prostate samples it was also necessary to define the specific area 
in the photo that should be analyzed, because the prostate is a very heterogeneous 
tissue and the risk for false negative cells should be minimized. After analysis all data 
were shown in a report. 
For each sample a ratio of all positive cells to all analyzed cells was calculated. For each 
staining with 5 mice, with 3 pictures each, mean values were calculated. With these 
means an unpaired T-test was done for each staining group. If the P-value was under 
0.05 the mean values of the various groups (genotypes) were considered to differ 
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significantly. For cre+ PTEN fl/+ cJun fl/+ JunB fl/fl with one sample, a statistical 
analysis with HistoquestTM was not feasible. 
The coefficient of variation (Cv) was not calculated for the results of the Histoquest
TM 
program. In some cases of the IHC experiments the means of the expression levels 
were nearing zero and therefore the Cv is not useful. For the Cv to be meaningful the 
means have to be rather high, otherwise also a small standard deviation can cause an 
immense cv even when the difference is minimal. 
 
6.5. Western Blot 
6.5.1. Protein Lysates 
For preparing the protein lysates from the prostate samples that were stored at -80 °C, 
IP-buffer + Inhibitors were used. The frozen prostate tissue was placed into a douncer 
and 250 µl IP-buffer + Inhibitors was added. The prostate sample was dounced until it 
was homogenized. The whole douncing process was done on ice. After 
homogenization the sample was shaken for 1 h at 4 °C and then centrifuged for 30 min 
at 4 °C at 13000 rpm (15682 x g). The supernatant was taken and centrifuged a second 
time for 20 min at 4 °C at 13000 rpm (15682 x g). After this step the supernatant was 
ready to use for western blotting or, alternatively, stored at -80 °C. 
IP-buffer      
6.5.2. Protein Concentration with Bradford Assay 
IP-buffer with Inhibitors 
25 mM HEPES pH7.5     1 ml IP-buffer 
150 mM NaCl      40 µl Protease Inhibitors  
10 mM EDTA pH8     10 µl Aprotinin 1 mg/ml 
10 mM beta glycerolphosphate   10 µl PMSF 100 mM  
0.1 % Tween 20     2 µl NaF 500 mM 
0.5 % NP-40      10 µl Na Van 100 mM 
stored at room temperature    1 µl Leupeptin 1 µg/µl 
       freshly prepared on ice 
To measure the protein concentration of the prostate samples the Pierce Coomassie 
Plus (Bradford) Protein Assay (Thermo Scientific, Massachusetts, USA) was used. This is 
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a calorimetric protein assay based on the dye Coomassie Brilliant blue G-250. Under 
acidic conditions and in occurrence of proteins the red form of the dye is converted to 
its blue form. The colorimetric measurement was done with a spectrophotometer  
(U-2000, Hitachi, Japan) at 595 nm. To interpret the results a BSA standard line was 
prepared and measured right before the prostate samples. 
6.5.3. Western Blotting 
For Western Blotting 40 µg of sample protein was loaded. Therefore the following 
calculation was used. The desired amount of protein (40 µg) was divided by the protein 
lysate concentration in µg/µl measured with the Bradford Assay. The calculated 
amount of protein lysate (in µl) was filled up to 5 µl with IP-buffer + Inhibitors. In the 
next step 5 µl Laemmli sample buffer (2x SDS gel-loading dye) was added. The ratio of 
protein lysates with IP-buffer/ sample buffer is 1:1. This solution was heated up to 
95 °C for 7 min. After heating, the samples were put on ice and centrifuged briefly. The 
complete 10 µl were applied on the gel. The gel is a 5-15 % Tris-Glycine  
SDS-Polyacrylamide gel. The gel was run at 120 V in electrophoresis buffer. To 
interpret the bands a prestained protein ladder (Thermo Scientific, Massachusetts, 
USA) was used. After electrophoresis the gel and a piece of nitrocellulose (Merck 
Millipore, Germany) was put in a transfer chamber. The exact arrangement for this 
transfer sandwich is shown in the illustration below. The transfer was run over night at 
20 V in a 20 % methanol transfer buffer. 
2x SDS gel-loading dye  Transfer Arrangement 
100 mM Tris-HCL pH 6,8  
200 mM DTT 
4 % SDS 
20 % Glycerol 
 
 
20 mg Bromphenol blue 
filled up to 20 ml with aqua dest. 
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Electrophoresis buffer  Transfer buffer 
 
144 g Glycine    112 g Glycine 
30 g   Tris    24.5 g Tris 
10 g   SDS    20 % Methanol 
filled up to 10 l with aqua dest. filled up to 10 l with aqua dest. 
 
TBS-T pH 7.5    
Primary Antibody 
Ponceau solution 
6.5 g Tris    0.1 % Ponceau 
9 g NaCl    5 % Acetic acid 
0.1 % Tween 20 
filled up to 1 l with aqua dest. 
After transferring the proteins onto the nitrocellulose all proteins were stained with 
Ponceau solution to check if the transfer was successful. The Ponceau solution was 
then washed off with TBS-T for 10 min. 
In the next step the proteins were blocked with 5 % dry milk in TBS-T for 1 h at room 
temperature. After blocking the nitrocellulose was washed again with TBS-T for 
15 min. The nitrocellulose was incubated with primary antibody over night at 4 °C 
while shaking. As loading control a beta actin antibody was used. The primary antibody 
was then removed and the nitrocellulose was washed with TBS-T for 30 min while 
shaking. 
The exact information on primary antibodies, used concentrations and their particular 
secondary antibodies can be looked up in the table below. 
Company Concentration Secondary Antibody 
Beta Actin CS 4967 1:1000 anti rabbit 
cJun SC 1694 1:200 anti rabbit 
JunB SC 73X 1:2000 anti rabbit 
Androgen Receptor SC 816 1:1000 anti rabbit 
p16 SC 74401 1:200 anti mouse 
p21 SC 397 1:1000 anti rabbit 
p27 SC 1641 1:200 anti mouse 
PTEN CS 9559 1:1000 anti rabbit 
p-serAkt CS 4058 1:1000 anti rabbit 
Pan Akt CS 4685 1:1000 anti rabbit 
Table 5 Used antibodies and their conditions for WB. CS: Cell Signaling Technology (Massachusetts, 
USA); SC: Santa Cruz Biotechnology (California, USA). 
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The nitrocellulose was then incubated with the secondary antibody for 1 h at room 
temperature while shaking. The concentration for the secondary antibody was 1:5000 
in TBS-T. After 1 h incubation the secondary antibody was removed and the 
nitrocellulose was washed a last time with TBS-T for 45 min. 
For visualization of the immune reaction the ECL Plus Western Blotting Detection 
System (GE Healthcare, UK) was used. Both solutions were poured on the 
nitrocellulose and after 5 min incubation time the chemiluminescent signal (Luminol) 
was analyzed with a LUMI Imager F1 (Boehringer, Germany). 
 
Figure 17: Scheme of the functionality of the WB reaction. After transferring, the antigen is located on 
nitrocellulose and treated with primary and secondary antibody. The second antibody is marked with 
HRP that in turn catalyzes the reaction with the ECL detection reagent to Luminol. The amount of 
conversion corresponds to the intensity of Luminol, which is then detected by a Lumi Imager 
[modified from http://www.crbdiscovery.com/newsletter/MAY.html]. 
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7. Results 
 
7.1. Breeding 
In the first breeding PTENpc+/- and PTENpc-/- mice were generated. The bodyweight, the 
weight of the prostate tissue, and images of the whole prostate were compared 
between wt, PTENpc+/- and PTENpc-/- prostate samples.  
The comparison of the body weight analyzed with an unpaired T-Test showed no 
significant differences between the genotypes (Figure 18). The bodyweight in PTENpc+/- 
and PTENpc-/- mice was slightly higher than the bodyweight in wt mice. 
A significant difference was detected in the weight of the prostate tissue. In PTENpc-/- 
mice the prostate was enlarged compared to wt and PTENpc+/- prostates (Figure 19). No 
difference could be found in the prostate weight of wt mice as compared to PTENpc+/- 
mice. The coefficient of variation for each column (mouse bodyweight and prostate 
weight) was always below 0.5, or 50% respectively. That shows that the determined 
means typify all data (Table 6). 
 
 
 
 
 
 
 
 
 
Figure 19: Statistical Analysis of the 
mouse bodyweight by an unpaired T-
Test shown with bar graphs. No 
significant differences in the means of 
the bodyweight could be detected 
between wt, PTENpc+/- and PTENpc-/-. 
Figure 18: Statistical Analysis of the 
mouse prostate weight by an unpaired T-
Test shown with bar graphs. PTEN 
knockout prostate samples were 
significantly bigger than wt and PTENpc+/- 
prostate samples. 
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Bodyweight 
Mice 
   Weight 
Prostate 
   
 wt PTENpc+/
- 
PTENpc-/-  wt PTENpc+/- PTENpc-/- 
Mean ( x ) 31.35 g 34.34 g 34.62 g Mean ( x ) 181.8 mg 183.1 mg 453.0 mg 
Std. 
Deviation 
(SD) 3.771 4.156 4.183 
Std. 
Deviation 
(SD) 43.23 45.86 46.20 
Coefficient 
of Variation 
(CV) 12.0% 12.1% 12.1% 
Coefficient 
of Variation 
(CV) 23.8% 25.0% 10.2% 
Table 6: Coefficient of Variation (Cv) shown for wt, PTEN
pc+/-and PTENpc-/- respectively for the mouse 
bodyweight and the weight of the mouse prostate.  The Cv was always under 50%, which 
demonstrates, that the means typify the data. 
The difference in prostate size was also noticeable in the prostate images. The prostate 
tissue of PTENpc-/- was enlarged as compared to wt and PTENpc+/-. Between wt and 
PTENpc+/- no significant macroscopic differences were observed (Figure 20).  
 
 
The PTENpc-/- mice were intercrossed with cJun and JunB floxed mice. 
For PTEN the offspring always showed the genotype of Δ/+. The Delta allele results 
from a PTEN knock out in the whole organism and was determined by PCR genotyping. 
The genotypes for JunB and cJun did not always occur in the expected Mendelian 
frequency. For cJun this is shown in Figure 21. Just double bands representing the fl/+ 
genotype should have occurred, but single upper bands (fl/fl) and single lower bands 
(+/+) were also visible. 
Figure 20: Macroscopic images of the urogenital tract of mice. The prostate of PTEN knockout 
mice (c) is enlarged as compared to the wildtype (a) and the cre+ PTEN fl/+ (b) prostates. 
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Figure 5: 
Left image: cre + PTEN 
fl/+ cjunfl/fl, JunBfl/+ 
mouse prostate 
Right image: cre + PTEN 
fl/+ cjunfl/+, JunBfl/fl 
mouse prostate 
 
 
Figure 21: Results of the PCR for the cJun genotyping with a 2% Agarose gel and Midori Green using a 
100 bp ladder (Lane1). The floxed cJun band is shown at 320bp (Lane 2) and the wt cJun band at 
280bp (Lane 4). Only double bands should appear, showing fl/+ genotypes, yet we found a mixture of 
fl/fl, fl/+ and +/+ genotypes. 
To generate the PTEN cJun and/or JunB knockouts only mice with the expected fl/+ or 
Δ/+ were used for breeding. The resulting generation offered various genotypes but no 
cJun, JunB double knockout and no cJun or JunB single knockout mice. Also for PTEN 
no homozygote knockout was recognized. For further experiments male mice with the 
following genotypes were analyzed: cre+ PTEN fl/+ with cJun fl/+ JunB fl/+ or cJun fl/fl 
JunB fl/+ or cJun fl/+ JunB fl/fl. 
 
Figure 22: Macroscopic images of the urogenital tract of mice. No differences were found between the 
prostates of the PTENpc+/-cJunpc-/-JunBpc+/- (a) and the PTENpc+/-cJunpc+/-JunBpc-/- (b) mice. There were 
also no differences between the prostates in this table and the wt and PTENpc+/- prostates shown in 
Figure 20. Especially no enlargement was observed like in the PTENpc-/-prostates. 
The number of mice per genotype was too small to give statistically relevant data  
(4 mice with cJun-/- JunB+/- and 1 mouse with cJun+/-JunB-/-), but it seems that the body- 
and the prostate weight are comparable with the wt and PTENpc+/-. Additionally the 
macroscopic images showed that the prostates of cJun and JunB knockouts are 
comparable to the wt and PTENpc+/-. A massive enlargement of the prostate, as 
observed in PTENpc-/-, could not be observed (Figure 22). 
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7.2. HE’s 
Analysis of the HE staining showed the characteristic histological differences between 
wt, PTENpc+/- and PTENpc-/- prostate tissue. Characteristic signs are marked with an 
arrow in the images of Figure 23. 
The normal prostate tissue was found in wt mice. The PTENpc+/- mice showed 
precancerous signs like those found in human prostatic intraepithelial neoplasia, either as 
low grade PIN (LGPIN) or high grade PIN (HGPIN). The cytological changes of PIN are 
characterized by presence of nucleoli, increase of nuclear to cytoplasmic ratio and 
increased nuclear size. (24c).The secretory cell layers showed signs of intraluminal 
papillary proliferation (24d) and only few residual basal cells were recognized. 
In the PTEN knockout mice LGPIN, HGPIN and prostate cancer formation were 
identified. In some regions the basal layer was absent (24e). In such regions an 
invasion into the stroma or luminal fusion was observed (24f). Enlarged nuclei and 
many prominent nucleoli were observed, too. 
Most precancerous and cancer incidences were seen in the PTENpc-/- mice, whereas in 
PTENpc+/- mice only precancerous lesions were observed. 
In the second breeding HE stainings were done for PTENpc+/-cJunpc+/-; PTENpc+/-cJunpc-/-
JunBpc+/- and PTENpc+/-cJunpc+/-JunBpc-/-. 
Similar histological change was found comparing PTENpc+/-cJunpc+/- with PTENpc+/-. The 
intraluminal proliferation of the secretory cells in PTENpc+/-cJunpc+/- was as pronounced 
as in PTENpc+/- (24c, d and 25a, b). 
In PTENpc+/-cJunpc-/-JunBpc+/- signs of LGPIN, HGPIN and Prostate Cancer were identified. 
The severity of histological changes was as pronounced as in PTENpc-/-. The area of 
intraluminal proliferations was larger in PTENpc+/-cJunpc-/-JunBpc+/- as compared to 
PTENpc-/- mice (25c and 24e). 
No histological change was found comparing PTENpc+/-cJunpc+/-JunBpc-/- with PTENpc+/-. 
The level of intraluminal proliferation of secretory cells and also their cytological 
changes were comparable to PTENpc+/- (24c, d and 25e, f). 
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Figure 23: HE stainings show characteristic histological differences in the prostate tissue of wt (a, b), 
PTENpc+/- (c, d) and PTENpc-/- (e, f) mice (scale bar 50µm). Characteristic signs are shown with an arrow. 
In wt with normal prostate tissue a connective tissue between adjacent glands and uniform nuclei are 
visible (arrows 24a). Many basal cells surround the glands (24b). In PTENpc+/- precancerous signs like 
presence of nucleoli, increase of nuclear to cytoplasmic ratio and increased nuclear size (24c) and the 
beginning of intraluminal papillary proliferations (24d) are visible. In PTEN knockout prostate tissue 
prostate cancer marks like massive intraluminal proliferation (24e), an absent basal layer (24e) and 
luminal fusion of the glands (24f) are visible. 
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Figure 24: HE stainings show characteristic histological differences in the prostate tissue of PTENpc+/-
cJunpc+/- (a, b), PTENpc+/-cJunpc-/-JunBpc+/- (c, d) and PTENpc+/-cJunpc+/-JunBpc-/- mice (scale bar left side 
50µm, right side 25µm). Similar histological alterations were found comparing PTENpc+/-cJunpc+/- and 
PTENpc+/-cJunpc+/-JunBpc-/- and PTENpc+/- (Figure 23c, d). Signs of massive intraluminal proliferation of 
secretory cells in cre+ PTENpc+/-cJunpc-/-JunBpc+/- (25c) were more pronounced compared to PTENpc-/- 
(24e). 
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7.3. IHC 
7.3.1. Androgen Receptor 
There was no significant change in the expression of Androgen Receptor in wt and 
PTENpc+/-. In the mean value PTENpc+/- prostate tissue showed 2% higher AR activity 
than the wt prostate tissue (wt: 27.2 % and PTENpc+/-: 29.2%). 
 
Figure 25: Images of the IHC staining of mice prostates tissue for Androgen Receptor (scale bar 
50 µm). Blue=nuclear hemalaun counterstaining, red=AR nuclear + cytoplasm. The highest AR 
activation was seen in PTENpc+/-cJunpc-/-JunBpc+/- and PTENpc-/- mice, and intermediate AR expression 
level in PTENpc+/- mice. The least AR activity was recognized in wt samples. 
A massive increase in AR activation was measured in PTENpc-/- and PTENpc+/-cJunpc-/-
JunBpc+/- prostates. Both genotypes showed an expression of AR in about 80% of cells, 
but the highest expression was observed in the cJun knockout prostate tissue    
(PTENpc-/-: 77.1% and PTENpc+/-cJunpc-/-JunBpc+/-: 81.6%) (Figure 25). The AR expression 
was significantly higher in the PTEN knockout and PTENpc+/-cJunpc-/-JunBpc+/- samples 
compared to the wt and PTENpc+/- prostate samples. 
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The expression levels of AR in PTENpc+/-cJunpc-/-JunBpc+/- was more pronounced 
compared to PTENpc-/-, however not statistically significant (p=0.5497) (Figure 26). 
The AR staining of the PTENpc+/-cJunpc+/-JunBpc-/- sample showed an AR activation in 
35.4% of the prostate epithelial cells. This AR activity is a little higher than observed in 
wt and PTENpc+/- but much less compared with PTENpc-/- and PTENpc+/-cJunpc-/-JunBpc+/- 
prostates (Figure 27). 
Figure 26: Comparison of theAR-
expression mean values with an unpaired 
T-Test. Mean values from the IHC of the 
AR were determined with HistoquestTM. 
No differences in the AR-Expression were 
observed between wt and PTENpc+/- 
prostate samples (both around 30%) and 
between PTEN knockout and PTENpc+/-
cJunpc-/-JunBpc+/- prostate samples (both 
around 80%). The AR-expression was 
significantly higher in PTEN knockout and 
PTEN cJun knockout samples compared to 
wt and PTENpc+/- samples. 
Figure 27: Image of the AR staining of the single prostate tissue sample of PTENpc+/-cJunpc+/-JunBpc-/- 
(a) (scale bar 50µm). Blue=nuclear hemalaun counterstaining, red=AR nuclear + cytoplasm. Its 
activity is a little higher compared to wt and PTENpc+/- but much lower compared to PTENpc-/- (b) and 
PTENpc+/-cJunpc-/-JunBpc+/-. 
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7.3.2. cJun 
The genotypes of wt, PTENpc+/- and PTENpc+/-cJunpc-/-JunBpc+/- showed almost no 
detectable cJun expression. Only very few positive cells using cJun Abs were 
recognized. 
In prostate tissue after loss of PTEN an increase of the expression of cJun up to 4.5% 
was recognized. However, due to low sample number the difference between PTEN 
knockout samples and wt, PTENpc+/- and PTENpc+/-cJunpc-/-JunBpc+/- was not statistically 
significant (Figure 28, Figure 29). 
 
Figure 28: Images of the IHC staining of mice prostate tissue cJun (scale bar 50 µm). Blue=nuclear 
hemalaun counterstaining, red=cJun nuclear + cytoplasm. Almost no cJun expression was detectable 
in wt (a), PTENpc+/- (b) and PTENpc+/-cJunpc-/-JunBpc+/- (d). In PTENpc-/- (c) the cJun activity was highly 
increased. 
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Figure 29: Comparison of the cJun 
expression mean values with an unpaired 
T-Test. Almost no cJun expression was 
detectable in wt, PTENpc+/- and PTENpc+/-
cJunpc-/-JunBpc+/-. The cJun expression was 
increased in PTENpc-/- prostate tissue. 
However, the cJun expression was not 
significantly different to wt, PTENpc+/- and 
PTENpc+/-cJunpc-/-JunBpc+/-. 
 
 
 
 
 
The cJun staining of the PTENpc+/-cJunpc+/-JunBpc-/- sample showed 5% cJun positive 
cells. The observed cJun activity was as high as the cJun activity in PTENpc-/- (Figure 30). 
Figure 30: Image of the cJun staining of the single prostate tissue sample of PTENpc+/-cJunpc+/-JunBpc-/- 
(a) (scale bar 50 µm). Blue=nuclear hemalaun counterstaining, red=cJun nuclear + cytoplasm. The cJun 
activity of PTENpc+/-cJunpc+/-JunBpc-/- was as high as in PTENpc-/- (b). 
When looking at the data for the cJun stained samples, a qualitative approach seems 
indicated, possibly even more than a quantitative approach. Therefore, an unpaired  
t-test analysis was done comparing the number of samples that include cells with high 
cJun expressions in the IHC. In total numbers these were 0/5 samples in the wildtype 
group, 4/5 samples in the PTENpc-/- group, 0/5 samples in the PTENpc+/- group, and 0/4 
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samples in the PTENpc+/-cJunpc-/-JunBpc+/- group. After manually going through the slides 
we came to the conclusion, that the few cells, which have been marked in the IHC of 
the PTENpc+/-cJunpc-/-JunBpc+/- group, did not meet the criteria of highly cJun expressing 
cells and must therefore, be regarded as artifacts. 
The T-test showed that the differences between the PTENpc-/- group and the wildtype, 
PTENpc+/-, and PTENpc+/-cJunpc-/-JunBpc+/- groups were highly significant (p = 0.0039; 
0.0039; and 0.0096 respectively) (data not shown). 
7.3.3. JunB 
The JunB expression analysis with IHC comparing mean values with an unpaired T-Test 
showed an increase from wt prostate samples with almost no JunB positive cells 
(0.32%) to PTENpc+/- with around 2% positive cells and up to 6% positive cells in the 
 
Figure 31: Images of the JunB IHC staining of mouse prostates tissue (scale bar 50 µm). Blue=nuclear 
hemalaun counterstaining, red=JunB nuclear + cytoplasm. A slight increase of JunB expression was 
observed from wt (a) with almost no JunB expression to PTENpc+/- (b) with around 2% positive cells to 
cre+ PTENpc-/- (c) with 6% JunB expression. A massive increase in the JunB expression was observed in 
PTENpc+/-cJunpc-/-JunBpc+/-with almost 19% JunB positive cells (d). 
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tumor tissue of PTENpc-/-. In PTENpc+/-cJunpc-/-JunBpc+/- an elevated JunB expression of 
18.9% positive cells was identified, although one allele of JunB was knocked out in this 
genotype (Figure 31, Figure 32). 
 
Figure 32: Comparison of the JunB mean 
expression values using an unpaired T-Test. JunB 
expression was lowest in wt-mice, slightly 
increased in PTENpc+/-and about twice as high in 
PTENpc-/- (Yet below 10%). JunB expression was by 
far highest in PTENpc+/-cJunpc-/-JunBpc+/- mice (up to 
20%). However, this difference was not 
significant. 
 
 
In the PTENpc+/-cJunpc+/-JunBpc-/- sample the JunB staining showed no positive cells in 
the prostate tissue (Figure 33a). 
 
Figure 33: Image of the JunB staining of the single prostate tissue sample of PTENpc+/-cJunpc+/-  
JunBpc-/- (a) (scale bar 50 µm). Blue=nuclear hemalaun counterstaining, red=JunB nuclear + 
cytoplasm. JunB staining in the PTENpc+/-cJunpc+/-JunBpc-/- mouse showed no positive cells compared 
to PTENpc+/-cJunpc-/-JunBpc+/- (b) mice increased JunB expression. 
51 
 
 
7.3.4. Ki67 
A slight increase in Ki67 expression was found in PTENpc+/- with 3.35% positive cells 
compared to wt with 3.03%. The tumor tissue of PTENpc-/- showed a significantly higher 
ki67 activity (8.28%) compared to wt and PTENpc+/-. In PTENpc+/-cJunpc-/-JunBpc+/- the 
activation of ki67 was massively increased with 18.19% positive cells. However, this 
increase in Ki67 activation was not statistically significant compared to wt, PTENpc+/- 
and PTENpc-/- (Figure 34, Figure 35).  
 
Figure 34: Images of the IHC staining of mice prostates tissue Ki67 (scale bar 50 µm). Blue=nuclear 
hemalaun counterstaining, red=Ki67 nuclear + cytoplasm. An increase in Ki67 expression was 
observed from wt (a) over PTENpc+/- (b) to PTENpc-/- (c). PTENpc+/-cJunpc-/-JunBpc+/- showed the highest 
Ki67 activity. 
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Figure 35: Comparison of the Ki67 expression 
mean values with an unpaired T-Test. Almost 
no change in Ki67 expression was observed in 
wt (3%) Ki67 expression compared to 
PTENpc+/-  (3.3%). A significant increase in the 
Ki67 expression was recognized in PTENpc-/- 
compared to wt and PTENpc+/-. The highest 
Ki67 expression was observed in PTENpc+/-
cJunpc-/-JunBpc+/- with 18% Ki67 positive cells.  
 
 
 
 
 
In the prostate tissue of the PTENpc+/-cJunpc+/-JunBpc-/- sample a low activity of ki67 
(1.58%) was detected. The expression level was lower than observed in wt and 
PTENpc+/- (Figure 36). 
 
 
 
 
 
Figure 36: Image of the Ki67 staining of the single prostate tissue sample of PTENpc+/-cJunpc+/-
JunBpc-/- (a) (scale bar 50 µm). Blue=nuclear hemalaun counterstaining, red=Ki67 nuclear + 
cytoplasm. Ki67 activity of PTENpc+/-cJunpc+/-JunBpc-/-was lower compared to wt and cre+ PTENpc+/- 
(b). 
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7.4. Western blot analysis 
We analyzed expression levels of total prostate tissue by western blot of wt, PTENpc+/-, 
and PTENpc-/- (n=3 each).  
No differences were recognized in the expression of AR in wt compared to PTENpc-/-. In 
PTENpc+/- AR activation was increased in PTENpc-/- compared to wt. In accordance with 
the datasheet of the AR antibody the bands for the AR should be seen at 110 kDa but 
they were recognized at 160 kDa. 
 
Figure 37: Picture of WB with 3 different samples per genotype. Loading control was beta Actin. Side 
note: Beta-actin, JunB and cJun bands shown have not been taken from the same blot, yet from blots 
with same concentrations. This collage was necessary, as these three proteins could not be 
distinguished on one blot. 
The WB was repeated several times with the same result. Because of this discrepancy 
in molecular weight the results of AR expression should be evaluated critically. In this 
case the IHC of the AR is more meaningful. 
JunB and cJun expression was lowest in wt prostates. In PTENpc+/- the JunB and cJun 
expression was slightly elevated but in PTENpc-/- it was highly increased. 
Similarly, p27 expression was increased in PTENpc-/- compared to wt and PTENpc+/- 
prostates. 
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For p-serAkt expression an increased expression in PTENpc+/- to PTENpc-/- compared to 
wt was seen (Figure 37). 
The expression of p16 and p65 was higher in PTENpc-/- compared to wt. However, the 
tumor suppressor p53 was expressed at a higher level in wt than in PTEN knock out 
prostate tissue (Figure 38).  
 
 
Figure 38: Picture of WB with 2 different samples per genotype. Loading control was beta Actin. Side 
note: Beta-actin, P53 and P65 bands have been taken from different blots using equal sample 
concentrations. 
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8. Discussion 
 
The effects of cJun and JunB on cancer range from tumor suppressor to oncogenic 
action. In PCa their role is discussed controversially. To better understand the 
influences of these two AP1 members on PCa we took advantage of a PCa mouse 
model (PTENpc-/-) where we also did an additional knockout of cJun and/or JunB. 
In this master thesis we tried to get genotypes for PTEN+/-, PTENpc-/-, PTENpc-/-cJunpc-/-
JunBpc-/-, PTENpc-/-cJunpc-/-JunBpc+/+, PTENpc-/-cJunpc+/+JunBpc-/-. 
The first attempted breeding was successful. Prostates of the PTENpc-/- showed the 
expected enlargement due to the massive tumor development. Mice with the 
genotype of wt and PTENpc+/- showed a normal macroscopic prostate and the weight of 
the prostate in both genotypes was significantly smaller as compared to PTENpc-/-. 
Values indicated by Cv were representative. 
The second generation was showing problems in the genotype. During this breeding 
female cre+ PTEN fl/fl and male cre- cJun fl/fl JunB fl/fl were crossed. Female cre+ 
PTEN fl/fl were used for this breeding since males with this genotype are usually 
unable to breed due to proceeding PCa. 
Instead of the expected genotype PTEN fl/+ in the first generation PTEN Δ/+ genotypes 
occurred in the entire brood. For cJun and JunB not only fl/+ but also fl/fl and +/+ was 
observed in the offspring.  
An explanation for this phenomenon could be that during the breeding with PB-Cre4 
mice small foci of expression of Cre were seen not only in the specific tissue but also in 
seminal vesicals, testis and ovaries. In contrast to the testicular expression, the Cre 
expression in the ovaries has an influence on the floxed alleles. It has been shown that 
in cre+ females, oocyte mediated recombination can occur [WU et al., 2001]. 
This recombination would explain the Δ PTEN allele in mice at 3-4 weeks of age. One 
allele of the PTEN gene is already excised in embryogenesis. Whether the genotypes of 
cJun and JunB are possibly also explainable with the PB-Cre4 females remains unclear. 
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There are different options to solve this PTEN breeding problem. One could try to use 
male cre+ PTEN fl/fl mice for the breeding as soon as possible before they become 
infertile within approximately 12 weeks. Another option is to cross male cre+ PTEN fl/+ 
mice with female cre- cJun fl/fl JunB fl/fl mice. The advantage is that male mice 
become infertile only after approximately 9 months and can therefore have more 
offspring. On the other hand this breeding pattern takes more time to produce the 
desired genotype. In contrast to the first breeding method only some mice will 
manifest PTEN fl/+,which is the desired genotype for the next breeding to achieve the 
final genotype of PTEN fl/fl with cJun, JunB double or single knock out. 
There are alternative methods for prostate specific Cre activity available. A relatively 
new method is to use an inducible Probasin Cre. 
The advantage is that the researcher can choose the moment to induce the Cre. This is 
useful in the case of prostate cancer because this is a disease mainly occurring in 
elderly men. Instead of the PB-Cre4 that is already active in the young adult, the 
inducible Cre can be activated in older mice. Birbach et al. developed a mouse line 
expressing an inducible Cre protein (MerCreMer).This Cre is controlled by regulatory 
elements of the Probasin gene on a bacterial artificial chromosome (BAC). The 
induction of the MerCreMer occurs via Tamoxifen. The Cre shows a high controllability 
and no background recombination [BIRCHBACH et al., 2009]. 
Therefore it seems that the inducible Cre could be the solution to the breeding 
problems caused by the imprinting of the Probasin gene mentioned above. 
To get at least some insight on the issue whether cJun and JunB work as tumor 
suppressors or inducers, the cJun and JunB knockouts with the following genotypes 
were analyzed:  
1. PTENpc+/-cJunpc+/-, 2. PTENpc+/-cJunpc-/-JunBpc+/- and 3. PTENpc+/-cJunpc+/-JunBpc-/- and 
appropriate controls. 
Some unexpected observations were made in PTENpc+/-cJunpc-/-JunBpc+/- prostates. 
These mice developed a histological pronounced PCa. Since the histology of PTENpc+/-
cJunpc+/-JunBpc-/- was similar to PTENpc+/-prostates, the loss of one additional cJun allele 
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seems to accelerate tumor development. Therefore we assume that cJun might act as 
a tumor suppressor in the prostate. Ongoing experiments in the lab using PTENpc-/-
cJunpc-/- should be able to elucidate this question. 
An interesting new analysis of Walker and Kennedy supports the idea of cJun acting as 
a tumor suppressor in PCa. They analyzed a human prostate online dataset of Taylor et 
al. (Cancer Cell 2010) with regard to the role of cJun expression in human PCa patients. 
Using a Kaplan-Meier analysis of survival, PCa patients with cJun loss were compared 
to PCa patients with cJun expression. The loss of cJun in PCa showed a highly 
significant decrease in the survival rate as compared to PCa patients with cJun 
expression (Hazard ratio: 11.2, p < 0.0001) (WALKER S and KENNEDY R., unpublished 
data). 
We were interested in looking at the protein expression profiles of AR, cJun, JunB and 
Ki67 in genotypes that were available at the time. 
AR-expression was highest in PTENpc-/-, intermediate in PTENpc+/-and lowest in the wt 
prostate samples. The expression of the AR obviously increases with the progression of 
the tumor. In the PTENpc+/-cJunpc-/-JunBpc+/- mice the expression of the AR was even a 
little higher than in PTENpc-/-. This result is interesting, because in cJunpc-/- only one 
allele of PTEN was knocked out, supporting the idea of cJun acting as a tumor 
suppressor. 
Ki67, a nuclear protein that is active in cellular proliferation, was also analyzed and its 
expression was also high in PTENpc-/-, it decreased in PTENpc+/- and was lowest in the wt 
prostate samples. Interestingly, Ki67 expression was also higher in the PTENpc+/-cJunpc-/-
JunBpc+/- mice compared to the other groups. 
The PTENpc+/-cJunpc+/-JunBpc-/- sample showed the lowest Ki67 activity supporting the 
observation that loss of JunB has little influence on PCa development.  
Taken together the results of the HE stainings and the IHC for AR and Ki67 indicate that 
the knockout of cJun increases the tumor development in PCa.  
Summarizing the results for the HE-stainings, Ki67 -and AR-staining the PTENpc+/-
cJunpc+/-JunBpc-/- are comparable to PTENpc+/- prostates and it seems that a JunB 
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knockout does not increase the tumor development, in contrast to PTENpc+/-cJunpc-/-
JunBpc+/- prostate, where we could see increased tumor development. 
For a better understanding of the previous data, also cJun and JunB expression profiles 
were established with IHC.  
The JunB expression is increasing from wt over PTENpc+/- to PTENpc-/- prostates. For cJun 
almost no expression was detected in the wt and PTENpc+/- prostate samples but in 
PTENpc-/- a high increase in cJun expression was observed. 
This increase of cJun and JunB expression from normal prostate tissue to prostate 
tumor tissue was also seen in the expression of AR and Ki67. These findings correlate 
with the JunB expression profiles by the previously presented study of Chandran et al. 
(increase of expression from wt to primary prostate tumors) but they differ 
considerably from the JunB expression in prostates established by Li et al., which 
showed a decrease in expression from normal prostate tissue to progressive PCa.  
One explanation for these differing results in expression profiles of prostate tissue 
could be an altered expression of specific genes after surgical interventions. A study of 
Lin et al. showed that the expression of genes like cJun and JunB can be increased after 
surgical manipulation of the prostate. An in situ prostate biopsy in patients with 
clinically localized prostate cancer showed low levels of cJun and JunB expression. 
Subsequent to this in situ biopsy a radical prostatectomy was performed and 
immediately after this surgical removal an ex vivo biopsy showed highly increased 
expression levels of cJun and JunB. The explanation for this observation is a stress 
induced activation of the JNK pathway. cJun and JunB are direct targets of this 
pathway and they seem to be activated by this JNK stress-response pathway. However, 
the size of the prostate is a limiting factor. Lin et al. showed that the difference in gene 
expression between in vivo and ex vivo biopsies decreases when the size of the 
prostate increases [LIN et al. 2006]. 
The study of Lin et al. showed that the method of providing the prostate tissue as well 
as the prostate size can influence the prostate gene expression. In the case of 
Chandran et al. different methods for providing the different prostate tissues were 
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accomplished and their expression profiles might be influenced by the different 
methods utilized. In our case all mice prostates, regardless of the genotype, were 
treated the same way. In consideration of the study of Lin et al. the expression of 
genes like cJun and JunB should be increased not only in the prostate tumor tissue but 
also in the normal prostate tissue because of the same activation by JNK stress 
response. This problem did not occur within mice prostate samples of this thesis since 
all samples were prepared the same way. 
Puhr et al. demonstrated that the expression of the AP-1 members cJun and JunB 
inversely correlate to the expression of the AR in different human prostate cell lines. 
This does not support our findings, specifically the positive correlation in the 
expression profiles of cJun, JunB and AR in mouse prostates observed in this thesis. In 
the mouse prostates cJun, JunB and AR expression increase from normal prostate 
tissue to PCa tissue. Possibly the results are not comparable in this case because of the 
different conditions between cell culture experiments and mouse models. 
Jin et al. found that a PTEN knock out in breast cancer cell lines activates cJun and JunB 
by unsuppressing the MAPK-pathway and further the JNK-pathway. This is another 
possible explanation for the increase of cJun and JunB in the PTEN knock-out mice 
compared to the wt [JIN et al., 2008]. 
As has been mentioned in the literature before, an increased level of JunB and 
especially of cJun in different tumors often correlates with their function as 
oncogenes. If this was the case in PCa, the knockout of cJun and JunB in mouse PCa 
should cause some tumor suppressive effects or at least no additional tumorigenic 
effects. Our findings showed that a knockout of cJun even drives the tumor 
development. This observation suggests that cJun might have tumor suppressor 
activities in the prostate. The knockout of JunB in the mouse prostate does not give 
such clear results but it has to be mentioned again that the analysis of one JunB 
knockout mouse can only give a rough idea of the involved processes, it is impossible 
to make meaningful conclusions. 
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The overexpression of cJun in PTENpc-/- mice might indicate that the tumor suppressor 
effects of cJun are suspended or covered up by other mechanisms. 
Another interesting observation was made concerning the cJun and JunB expression 
profile. In the PTENpc+/-cJunpc-/-JunBpc+/-genotype the JunB expression was increased 
massively. On the other hand, in the PTENpc+/-cJunpc+/-JunBpc-/- the cJun expression was 
greatly increased.  
It seems that cJun and JunB might be able to substitute for each other if one 
component is knocked out. 
It was described that JunB is able to substitute for the absence of cJun by a transgenic 
complementation approach and a knock-in strategy. In the embryonic development 
JunB knock-in can compensate the lack of cJun and prevents cardiac and liver defects, 
which usually occur in absence of cJun [Passegué et al., 2002]. 
WB-analysis was done to confirm the results of the IHC with focus on cell cycle protein 
expression. 
For cJun and JunB the results of Western Blotting confirm the results of the IHC-
analysis. An increase in protein expression was observed in wt compared to PTENpc+/- 
compared to PTENpc-/-. It seems that the expression of cJun and JunB increases the 
more prostate tumor progression occurs.  
Finally WB-analysis was done for p65, p53, p27, p16 and p-ser Akt. Alterations in the 
expression of these proteins play an important role in tumor progression. cJun and 
JunB are able to influence the cell cycle [PIECHACZYK and FARRAS, 2008]. With the 
measurements of these proteins it might be possible to get some more information 
about the influence of cJun and JunB in the tumor progression of PCa. 
The expression of the tumor suppressor p53 is decreased in the prostate tumor 
samples compared to the wildtype samples. This decrease is often observed in tumor 
development and one reason for the increased proliferation in tumor tissue. The 
increased levels of cJun in the prostate tumor tissue can influence the p53 expression, 
because, as it was mentioned before, cJun negatively regulates p53 by directly binding 
to the promoter region of p53 [SHAULIAN and KARIN, 2002]. 
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p27, a CDK-inhibitor mediates cell cycle arrest in G1 and thereby negatively regulates 
cell proliferation. The expression of p27 increased from wildtype compared to PTENpc+/- 
compared to PTENpc-/-. Studies from 1999 analyzing the expression of p27 in PCa 
showed different results. Fernandez et al., found a decreased expression of p27 in 
human PCa progression [FERNANDEZ et al., 1999]. Agus et al. also observed a low 
expression of p27 in prostate cancer cells, but a massive increase of expression was 
recognized after androgen withdrawal. The degradation of p27 in PCa seems to be 
androgen dependent [AGUS et al., 1999]. Therefore an androgen withdrawal 
experiment in the PTENpc-/- mice would be interesting. 
The crosstalk between the stroma and the epithelium of the prostate plays another 
important role in PCa development. 
Stromally expressed cJun in fibroblasts is able to influence the expression of p27 in 
prostate epithelial cells. cJun increase the production of IGF-1 in the stroma. IGF-1 was 
shown to upregulate the epithelial protein level of Akt, Cyclin D1 and MAPK whereas 
the p27 protein level is decreased. This cJun dependent IGF-1 production causes 
benign prostate hyperplasia-1 (BPH-1) cellular proliferation [LI et al., 2007]. 
These results are in contrast to the expression profile of p27 we found in PTENpc-/- 
mice. The protein level of p27 should also be analyzed by IHC, because with this 
method it is possible to specifically analyze prostate epithelial cells. 
The expression of the tumor suppressor p16 is increased in the PTENpc-/- prostate 
tumor tissue compared to the normal prostate tissue. 
In 1997, Halvorsen et al. also found an overexpression of p16 in the majority of 
prostate adenocarcinomas compared to hyperplastic or normal prostate glands. 
Explanations for this overexpression were rare. The frequency of point mutations of 
the p16 gene was analyzed, because mutations in critical genes play an important role 
in tumorigenesis in many other cancer types. For p16 a very low frequency of point 
mutations was detected and therefore cannot be used as an explanation for the 
overexpression. Other mechanisms, like the inactivation by methylation of the p16 
gene, were observed more frequently [HALVORSEN et al., 1997]. 
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cJun, which shows a higher expression in the tumor tissue, might be one regulator of 
p16(INK4a) in the prostate tissue. In 2011, Kollmann et al. discovered that cJun is able 
to prevent the methylation of p16 (INK4a). cJun stops the epigenetic silencing of the 
gene by binding to the promoter region and thereby precludes methylation of 
p16(INK4a) [KOLLMANN et al., 2011]. 
The expression pattern of JunB might be another explanation for the high expression 
of p16 in the prostate tumor tissue. It upregulates p16 and leads to dephosphorylation 
of pRb. In transient amplifying cells (basal cell population of the prostate epithelium) 
this mechanisms leads to senescence. If JunB is downregulated in these cells the level 
of p16 decreases and the cells are able to bypass senescence and proliferate again 
[KONISHI et al., 2008]. 
The protein kinase Akt was also analyzed because Akt is able to inhibit apoptosis and 
thereby promotes cell survival and it is negatively regulated by PTEN. The expression of 
Akt increased from wildtype to PTENpc-/-, which is not surprising on first sight. 
However, cJun probably also plays a role in Akt activation. As was mentioned before Li 
et al. showed that stromally expressed cJun in fibroblasts activates IGF-1 and thereby 
upregulates epithelial protein level of Akt [LI et al., 2007]. 
NFκB deregulation has often been observed in cancer progression. In many types of 
cancer including PCa NFκB expression is increased. To investigate the expression of 
NFκB in the used mouse model, p65 antibody, a subunit of NFκB, was used. The 
expression of p65 increased in PTENpc-/- compared to the wildtype prostate tissue. 
Little is known about direct mechanisms of AP-1 that modulate the NFκB-pathway. In a 
study of Sanchez-Perez in 2002 a crosstalk between cJun and NFκB was observed. The 
chemotherapeutic agent cisplatin induces apoptosis via activation of JNK-pathway. In 
cisplatin treated human embryonic kidney fibroblasts cJun is able to inhibit NFκB, 
thereby inducing apoptosis. Cisplatin treated fibroblasts with cJun -/- showed no 
inhibition of NFκB and lead to cell survival [SANCHEZ-PEREZ et al., 2002]. 
Taken together, many of the observations made in the experiments of this master 
thesis support the idea of cJun acting as a tumor suppressor. For JunB the results do 
63 
 
 
not show such clear tendency. A relationship between the AR and cJun, JunB seen in 
the data of Puhr et al. could not be confirmed. 
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9. Conclusion 
 
In this master thesis a PB-Cre4 (PTENpc-/-) mouse model was used to analyze the effect 
of cJun and JunB in PCa. cJun and JunB knockout strains were inbred to increase the 
amount of information. 
In the breeding of PB-Cre4 females with male cJun fl/fl JunB fl/fl various problems with 
the resulting genotypes occurred. This was probably due to the oocyte mediated 
recombination using female PB-Cre4 mice [WU et al 2001]. In further studies male PB-
Cre4 mice might be used and crossed as soon as possible before they become infertile. 
If this method does not show the predicted outcome an inducible Cre as described by 
Birbach et al. would be another option to achieve the volitional genotypes. 
The first aim of this master thesis was to describe the effects of cJun and JunB in PCa. 
After analyzing all results it seems that cJun acts as tumor suppressor in PCa. The 
tumor development was equal or even more pronounced in prostates with cJun 
knocked out as compared to prostates with only a PTEN knockout (PTENpc+/-cJunpc-/-
JunBpc+/- vs. PTENpc-/-) although in the cJun knockout mice only one allele of PTEN was 
knocked out. It will be interesting to see the tumor development in the genotype of 
PTENpc-/-cJunpc-/- in further studies. The expression of Ki67 and the AR was also 
increased in PTENpc+/-cJunpc-/-JunBpc+/- as compared to PTENpc-/-. The upregulated cJun 
activity in PTENpc-/- might be due to its tumor suppressor function that is suspended or 
covered up by other mechanisms.  
For JunB the results showed neither a tumor suppressor nor an oncogenic function in 
PCa. The knockout of JunB in the PTEN mouse model showed no change in the tumor 
development. In Ki67 and AR expression no change was observed compared to wt and 
PTENpc+/-. 
Another interesting observation concerning the relationship of cJun and JunB was 
made when cJun or JunB were knocked out. It seems that cJun and JunB can 
compensate for each other. In case of a cJun knock out, the JunB expression increased 
opposed to an increase in a cJun transcription when JunB was knocked out. 
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The second aim was to find out whether or not cJun, JunB and the AR can influence 
each other. After analyzing all data, no direct effect of cJun, JunB on the AR or vice 
versa was observed. The data of Puhr et al., reporting inverse expression of cJun/JunB 
and the AR could not be confirmed. 
Summarizing, the most promising observation in this master thesis was the tumor 
suppressor function of cJun in PCa in mouse models. This effect should be analyzed in 
further experiments especially with the additional genotypes that were missing in this 
thesis (PTENpc-/-cJunpc-/-JunBpc-/-, PTENpc-/-cJunpc-/-JunBpc+/+, PTENpc-/-cJunpc+/+JunBpc-/-).  
It would be interesting to understand the mechanisms behind the tumor suppressor 
function of cJun in more detail. One suggestion would be to do further analysis of the 
stromal epithelial crosstalk. Another interesting point would be to generate PTENpc-/-
cJunpc-/- and/or JunBpc-/- cell lines when the breeding was successful. With these cell 
lines more and easier experiments could be done including cell cycle experiments 
using FACS analysis. 
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